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Foot and mouth disease virus (FMDV) infects cloven-hoofed animals causing the highly contagious foot and mouth 
disease. It is spread by contact or through aerosol. The disease is often debilitating for infected animals and can be 
fatal. Severe measures are taken to contain outbreaks; quarantine and trade restrictions are imposed and herds with 
infected individuals are culled to prevent the spread of the disease. Consequently, outbreaks of the disease have 
drastic implications for agriculture and social economies which can be devastating for affected countries. There are 
seven serotypes of the virus; of which SAT1, SAT2, and SAT3 are endemic to Africa. South African buffalo populations 
such as those in the Kruger National Park, are natural carriers of FMDV (Thomson 1995). Careful monitoring and 
regular vaccination are necessary to detect and prevent outbreaks and the spread of the disease to livestock of 
neighbouring areas and farms. The vaccines currently used are inactivated FMDV virions. These are produced in cell 
culture, an expensive process that requires high levels of biosafety. Furthermore, inactivated virions present non-
structural proteins (NSPs) and thus cannot be distinguished from the infectious virus by imported ELISA kits that 
utilise the NSPs as coating antigens and conventionally produced detecting antibodies.  
We aimed to use recombinant constructs encoding the FMDV capsid and protease genes, cloned into the different 
vectors; pRIC, pEAQ and pTRAc, for transient expression in Nicotiana benthamiana to generate virus-like particles as 
an alternative vaccine candidate. Using a plant based expression system presents numerous advantages over the 
traditional cell culture production of the vaccine currently used. 
After having synthesised the FMDV genes P12A and 3C, the fusion gene P1-2A-3C (required for the vaccine) was 
cloned into these different plant expression vectors available in our laboratory. With Agrobacteria mediated 
infiltration of N. benthamiana, we demonstrated expression of recombinant protein by western blotting; and 
Coomassie stain, for each of the different constructs. Analytical ultra-centrifugation through a sucrose gradient was 
used to purify protein extracts. Comparison against a dilution series of bovine serum albumin was used to quantify 
the yield for each respective vector construct by densitometry. Transmission Electron Microscopy (TEM) imaging was 
used to qualitatively determine virus-like particle (VLP) assembly.  
In conclusion, we demonstrate proof of concept for a viable alternative approach for the production of a candidate 
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Frequently used Abbreviations 
BSA   bovine serum albumin 
DNA   deoxyribonucleic acid  
Dpi   days post-infiltration  
ELISA   enzyme-linked immunosorbant assay 
FMD   Foot and mouth disease 
FMDV   Foot and mouth disease virus 
His-tag   6 x histidine sequence 
LB  Luria-Bertani Broth media (composition detailed in appendix) 
LLB  Luria – Lennox Broth media (composition detailed in appendix) 
NSP  non-structural protein 
ORF   open reading frame 
PBS   phosphate buffered saline 
PCR   polymerase chain reaction 
P12A  oligopeptide of FMDV structural protein precursor 
P12A  Gene encoding the P12A oligopeptide 
P21A3C  oligopeptide of FMDV structural protein precursor with 3C protease included 
P12A3C  Gene encoding the P12A3C oligopeptide 
RNA   ribonucleic acid 
SAB   sample application buffer (composition detailed in appendix) 
SAT  Southern African territories serotype 
SDS   sodium dodecyl sulphate 
SDS-PAGE  sodium dodecyl sulphate - polyacrylamide gel electrophoresis 
TEM   transmission electron microscope 
VLP   virus-like particle  
SP  structural protein 





Introduction and Literature Review 
 
1.1 Economic importance and burden of Foot-and-Mouth Disease 
 
Foot and Mouth Disease (FMD) is the most economically devastating viral disease of domestic 
livestock (Wernery & Kaaden 2004). FMD infects ruminants and other cloven hoofed animals; of 
particular importance are livestock such as cattle, sheep, and pigs (Domingo et al. 2003). The disease 
is both highly infectious and contagious; spreading rapidly from one animal to another through air by 
inhalation of aerosols, by contact, either directly or via formites, or ingestion (Parthiban et al. 2015; 
Bravo De Rueda et al. 2014; Canadian Food Inspection Agency n.d.; Arzt et al. 2010). The rate of 
morbidity of this disease will often approach or reach 100% in immunologically naive animals 
(Jemberu et al. 2014). Because of the infectious and highly contagious nature of the disease, farmers 
in many areas are forced to cull entire herds of livestock in order to prevent the spread of the 
disease in the case of an infection (Bravo De Rueda et al. 2014). Outbreaks of foot and mouth 
disease thus have dire consequences; causing large numbers of livestock to be culled, entire regions 
to be quarantined, and trade bans to be implemented. The resulting financial toll on the farmers can 
be devastating, so too are the major impacts on the agricultural industries and economies of 
affected countries (Segarra & Rawson 2001; Robinson et al. 2016a). The outbreak of FMD in the 
United Kingdom during 2001 is estimated to have cost up to 8 billion Pounds and necessitated the 
slaughter of approximately 10 million sheep and cattle (Segarra & Rawson 2001). Quarantine 
measures taken in order to restrict the movement of infected animals and contain the disease also 
have an environmental impact on ecological conservation, limiting the movement of other animals 
in these areas (Somers & Hayward 2012).  
Animals infected by the disease can be symptomatic to varying degrees, among and within species 
Symptoms include: fever, blisters and calluses, or lesions on the feet, as well as lips, tongue, gums, 
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palate, and throat. Ruptured vesicles or blisters can be the source of much pain and discomfort for 
the animals. The severity of these ailments can be severely debilitating and will often render the 
animal lame. In some cases, infection can prove fatal, although the disease is not necessarily 
considered lethal. The mortality rate does not typically exceed 5% in adult livestock, although this 
varies among species and mortality may reach levels of over 75% in infant animals – suckling piglets 
may exhibit mortality rates of as much as 100% (Brown 1995). Death from FMD may come as a result 
of myocarditis (Stenfeldt et al. 2014). Infection can also drastically hamper milk production and this 
may persist indefinitely beyond the duration of the infection. The lesions created by the disease are 
also susceptible to secondary bacterial infections. In addition to this, those animals with ruptured 
lesions in the mouth, or rendered lame by the disease, cannot eat and typically also suffer from 
starvation. Studies characterising the pathogenesis of FMD have been conducted predominantly in 






The disease is caused by the foot and mouth disease virus (FMDV) of the Aphthovirus genus from the 
family Picornaviridea (Domingo et al. 2003). There are seven serotypes of this virus: type O, A, C, 
Southern Africa Territories 1 (SAT-1), SAT-2, SAT-3, and Asia-1 (Domingo et al. 2003). The distribution 
of each respective strain is illustrated in Figure 1.1. Infections by this virus have been recorded 
throughout the globe and it is regarded as endemic to areas in Africa, Asia and South America. The 
Buffalo (Syncerus caffer) populations of Southern Africa, such as those in the Kruger National Park, 
are typically natural and asymptomatic hosts of FMDV, specifically stereotypes SAT-1, 2, and 3. 
Buffalo thus act as reservoirs of the virus (Robinson et al. 2016a; Robinson et al. 2016c; Thomson 
1995). Animal containment with strict and rigorous screening and vaccination is necessary to 
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prevent the spread of the virus into the neighbouring farming regions. The continual screening and 




Figure 1.1: Countries in which respective serotypes of FMD were reported to the OIE between 1990 and 
2002. The data and maps were compiled by Nick Knowles and can be found at 
www.iah.bbsrc.ac.uk/virus/picornaviridae/aphthovirus. Image sourced from the review by Grubman 
and Baxt and reproduced with permission (Grubman & Baxt 2004) 
4 
 
1.2.2 Virus Structure 
FMDV is a single stranded RNA virus. The RNA is encapsulated in an icosahedral capsid constructed 
from 60 protomeric assemblies of four structural proteins, arranged in 12 pentameric copies. The 
capsid is typically 25 to 30 nm in diameter (Cao et al. 2009). The structure described is illustrated in 
Figure 1.2. The positive sense strand of RNA is translated into a single oligopeptide of the viral 
proteins upon entering the host cell. During translation, cleavage by the 2A protease yields the P12A 
subunit, subsequent cleavage by the 3C protease generates the VP0, VP1, and VP3. Finally upon 
assembly of the capsid; the VP0 precursor is cleaved to yield the VP2 and VP4 structural proteins 
(reviewed by Jamal & Belsham 2013). VP1, VP2, VP3 and VP4 thus comprise the structural proteins 
of FMDV derived from the P12A portion of the oligopeptide (Carrillo et al. 2005; Domingo et al. 
2003). However, VP4 exists within the interior of the viral capsid, unexposed, and consequently is 
not antigenic. Two documented sites that are of immunogenic importance are the GH loop and C 
terminus of the polypeptide, which both occur on VP1. The GH loop binds to the host cell surface via 
an integrin receptor to enable the entry of the virus (Logan et al. 1993; K. Strohaimer 1982; 
Martinez-Salas & Belsham 2017; Robinson et al. 2016d). The remaining P2 and P3 portions of the 
original oligopeptide comprise the precursors for the other non-structural proteins of FMDV. The 
virus induces high levels of translation of these viral proteins, which assemble into vast numbers of 
FMDV particles with encapsulated RNA within the host cell, thereby causing cell lysis, and thus 
releasing more live virus particles into the host. FMDV is likely the most rapidly replicating virus 
infecting mammalian cells; levels of viral RNA within cells equal that of cellular mRNA within a few 
hours (Martinez-Salas & Belsham 2017). Cell lysis can occur within 4 hours in infected ovine, bovine 





Figure 1.2. FMDV genome arrangement and particle structure morphology, presented in a review by Jamal and Belsham 




A vaccine is typically a protective inoculation prepared from a biological source that serves to induce 
a cellular and humoral immune response in the host animal against a specific pathogen. This 
provides the host with active acquired immunity to protect it against future exposure to the same 
pathogen. Such a vaccine that prevents future infection is referred to as a prophylactic vaccine. 
Traditionally these vaccines were developed by the inactivation of virulent pathogens to impede 
their infectious nature, and are hence termed inactivated vaccines. Inactivation is achieved through 
either radiation, antibiotic, chemical, or heat destruction of the virulent pathogen (Ebert 1998). 
Further research in the field of Immunology, and the underlying mechanisms and principles upon 
which vaccines induce protection, has led to the development of other forms of vaccines. These 
include attenuated vaccines, sub-unit vaccines, conjugate vaccines, as well as other experimental 
forms of vaccines. An attenuated vaccine is a cultivated form of a pathogen which has been 
modified, usually at a nucleic acid and amino acid level, in order to reduce the virulence of the 
pathogen. These are typically viral vaccines (Jane Flint 2009; Ebert 1998). Inactivated and attenuated 
vaccines constitute whole agent vaccines. A subunit vaccine, by comparison, introduces only a 
representative protein or portion of the pathogen to the host immune system. Recognition of the 
relevant epitopes confers future immune protection against the parent pathogen. Similarly, a 
conjugate vaccine is a molecular fusion of a poorly immunogenic molecule endogenous to a 
pathogen (often a polysaccharide) with a more immunogenic protein, in order to induce the 
necessary immune response and memory against pathogen molecular epitopes that are otherwise 
not typically immunogenic (Jane Flint 2009). 
 
1.3.1 Current vaccines for FMD 
Current vaccines in use against FMDV are live inactivated virus particles (Mignaqui et al. 2013; Li et 
al. 2016; Robinson et al. 2016b; Smitsaart & Bergmann 2017). These are expensive to produce and 
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require a high level of biosafety for their production prior to the point at which they are deactivated. 
Furthermore, the use of the live inactivated virus carries the risk of accidental spread of the 
infectious diseases. This can result from escape of the virus from production facilities, or by 
vaccination with incompletely inactivated vaccine virus particles that results instead in viral infection 
(Doel 2003; Robinson et al. 2016b). It is suspected that a confirmed case of infection in Normandy, 
Surrey in the United Kingdom during 2007 was caused by such an escape. The strain of the virus was 
identified to be the same 01 BFS 67-like strain (De Clercq et al. 2008; BBC 2007a) that was being 
used in a nearby animal health Institute facility for vaccine production (BBC 2007b). The strain is not 
commonly found in animals and was otherwise not seen since an outbreak in 1967. Following 
confirmation of the disease, all animals in the vicinity were culled the next day and a nationwide ban 
across Britain was imposed on the movement of cattle and pigs. A protection zone and increased 
surveillance zone was established and, in the next month, two more cases of FMD were confirmed in 
the Egham area 20km away (DEFRA 2007). All at risk animals in the Egham area were also culled. 
This is but one incident that emphasises the legitimacy for concern of biosafety and the severity of 
the implications associated with such a vaccine. In addition to these concerns of biosafety, and the 
high cost of production; another problem presented by the current vaccines used is that the live 
inactivated virus particles cannot be effectively distinguished from the infectious version of the virus 
by standard imported ELISA test kits (Mignaqui et al. 2013; Blanco et al. 2017). This is because the 
ELISA test kits use antibodies developed against the non-structural proteins, and the whole 
inactivated live virus also contains these non-structural proteins and so these proteins are present in 
vaccinated animals as well as infected animals. 
 
1.3.2 Aftovax vaccine  
Despite the prevalence of FMD in South Africa and the resulting demand for a vaccine against FMDV, 
no commercially available vaccines are produced within this country's borders. Efforts to control 
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FMD in this country currently rely on importing vaccines from neighbouring Botswana where they 
are produced by the Botswana Vaccine Institute in conjunction with MERIAL (Joemat-Pettersson 
2014). The produced vaccine is sold commercially branded as Aftovax. Aftovax is an inactivated foot 
and mouth disease virus composed of the five serotypes relevant to the region and incorporates the 
adjuvants aluminium hydroxide and saponin. The production process for Aftovax requires a period of 
41 days to develop the vaccine, complete with product testing (Botswana Vaccine Institute 2013). 
The vaccine is administered in young animals by injection and boosters are required every four to six 
months until the animal reaches adulthood (Merial 2013). 
1.3.3 Virus like particles 
Virus like particles (VLPs) are empty capsids that are structural and immunological replicas of the 
original virus, but do not contain the genomic DNA and non-structural proteins that makes the virus 
infectious and virulent, but are equally immunogenic (Li et al. 2016). Consequently, VLPs are not 
infectious and thus do not present the same safety concerns as using live inactivated virus. Hence 
production facilities for VLPs will not require the same level of biosafety precautions. VLPs thus offer 
huge potential as alternative vaccine candidates. VLPs can induce an immunogenic response, 
without presenting the non-structural proteins of the parent virus, thus enabling them to be 
distinguished from the live infectious forms of the virus. These reasons contribute to the growing 
popularity towards using VLPs as an alternative vaccination method. VLPs are produced via 
recombinant protein expression of the viral capsid structural proteins, with subsequent folding and 





1.4 Protein Expression 
The production of VLPs thus requires an expression system for the expression of the recombinant 
protein. Various protein expression systems exist and each presents its own advantages and 
shortcomings. More specifically relevant to this project, FMDV structural, non-structural, and 
indeed, as is our aim, entire viral capsids have been successfully expressed in a range of different 
expression systems. These systems include bacterial, yeast, insect and mammalian cell culture. 
1.4.1 Expression in a bacterial system 
A bacterial expression system is a well-established system and remains a typical favourite for the 
production of recombinant proteins in the pharmaceutical industry because of its low cost and high 
productivity. Bacterial expression systems have been used successfully for the production of 
recombinant protein in a number of bacterial species but are most well characterised by the species 
Escherichia coli. Bacteria such as E. coli can easily be cultured in large volumes and at high densities 
very rapidly to produce desired recombinant protein (Terpe 2006). This particular platform of 
expression is appealing because the E. coli can easily be transformed to include the genes for the 
recombinant protein. The extensive research done on E. coli has produced numerous strains specific 
for various purposes and has enabled the process to be well optimised. Specific strains and vectors 
compatible with E. coli have been designed to allow for selective induced expression by various 
selective promoters such as the araBAD promoter (PBAD), the L-rhamnose inducible rhaPBAD 
promoter and, relevant to work done in this project, the lac promoter (discussed later). 
 A major shortcoming of bacterial expression systems is that bacterial cells are not eukaryotic and 
consequently do not perform the same post-translational modifications of proteins as those of 
eukaryotic cells. There is no glycosylation of proteins and no chaperone proteins to assist in the 
nature of folding as it would in natural eukaryotic cells (Terpe 2006). This presents a major problem 
for expressing proteins, such as virus proteins to be used in vaccines; these require precise shape 
and confirmation in order to induce the required response in a host organism’s immune system. 
10 
 
Recognition of these viral proteins is essential for an immune response to recognise the appropriate 
antigen, and hence is essential to the working of a vaccine. Thus a bacterial expression system is 
limited in its ability to produce proteins capable of functioning as an effective candidate vaccine. In 
spite of the theoretical shortcomings of a bacterial expression system, FMDV VLPs have been 
successfully produced in E.coli with the ability to induce an immune response in cattle sufficient for 
protection against viral challenge (Xiao et al. 2016). 
1.4.2 Expression in a Yeast system 
Other platforms such as mammalian cell culture, insect cell culture, and yeast cell culture expression 
systems have been developed for the production of recombinant proteins, and have also been 
successful in the production of VLPS. Each of these expression systems make use of eukaryotic cells 
and thus avoid the shortcomings of a bacterial expression system, which fail to produce proteins 
with appropriate post-translational modification in heterogeneous recombinant proteins of 
eukaryotic origin. Proteins expressed in Saccharomyces cerevisiae, a yeast expression system, 
however show high levels of glycosylation and often hyperglycosylation (Punt et al. 2002). This level 
of glycosylation can effectively alter the topography of the protein surface and consequently impede 
the efficacy with which antibodies react to the protein since the sugar molecules mask original 
protein epitopes for which the antibodies are to be designed. Since vaccine efficacy relies on the 
recognition of the vaccine by the immune response-generated antibodies, this presents a major flaw 
in the use of a yeast expression system for the production of recombinant proteins and VLPs to serve 
as a candidate vaccine. Some strains of yeast have been developed that have decreased levels of 
glycosylation to address this shortcoming (Balamurugan et al. 2007). Rotavirus VP8, expressed in 
yeast, has been recorded to have successfully generated an immune response in mice and protected 
them from viral challenge (Andrés et al. 2006). The structural proteins of FMDV have also been 
successfully expressed in Pichia pastoris, a methylotrophic yeast, and used to protect guinea pigs 
against a viral challenge of the disease (Balamurugan et al. 2007). Few studies have successfully 
produced VLPs with yeast cells; a study developing rotavirus VLPs, after much vector modification, 
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was one such study (Rodríguez-Limas et al. 2011). The yeast expression platform is better suited to 
the production of non-enveloped VLPs (Kushnir et al. 2012). Improper particle formation and protein 
degradation are further problems encountered when using a yeast expression system for the 
production of VLPs. The low level of protein expression in individual cells fails to promote particle 
assembly. It has been further speculated that protein degradation becomes preferential when 
particle formation is limited (Rodríguez-Limas et al. 2011). 
 
1.4.3 Expression in insect cell culture systems  
A baculovirus-insect cell expression system presents an alternative eukaryotic expression system 
capable of complex post-translational modifications, protein folding and oligomerisations, while also 
accommodating high levels of accumulated heterologous protein. For the expression of recombinant 
protein in such a system; an insect cell is infected with the recombinant baculovirus containing the 
gene for the protein of interest: for the purpose of VLP production these will be the genes encoding 
the structural proteins of the virus. Once infected, the insect cell will then produce the desired 
protein encoded in the recombinant baculovirus genome. The cellular environment of insect cells 
will however vary from that of mammalian cells, the natural host environment of FMDV. Strict 
conditions are required for the correct assembly of VLPS which may not be met with the varying pH 
buffer capacity and other nutritional requirements of the insect cell (Cao et al. 2009; Mena et al. 
2006). Although a number of studies have successfully demonstrated the production of assembled 
VLPs by insect cell culture, the VLPs do not assemble within the insect cells, possibly on account of 
inappropriate pH of the insect cells (Cao et al. 2009). High FiveTM cells (HF cells) were used for the 
expression of FMDV P12A3C, generating empty capsid like particles that successfully elicited an 
immunogenic response in guinea pigs  which produced vast levels of FMDV specific antibodies as 
determined by ELISA tests (Cao et al. 2009).  
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The baculovirus-insect cell approach does however have the major disadvantage of requiring 
expensive culture media - thus making it expensive to scale up to an industrial scale. In addition to 
this, insect cells do not proliferate to the same extent as bacterial cells and so protein production is 
not as rapid in these cultures. This presents a problem for using this technology for the production of 
a commercial product. Another problem encountered with the use of an insect expression system for 
the production of recombinant protein is that not all species will reliably produce the desired protein. 
Only one out of three lepidopteran species tested was capable of producing VLP forming FMDV 
capsid proteins (Kumar & Jalali 2016) 
FMDV Serotype O is globally predominant, but Serotype O capsids are acid sensitive and as such 
Serotype O VLPs are not stable within the acidic conditions of insect haemolymph, thus presenting a 
further challenge with using insect expression. Though this challenge has been successfully addressed 
with the creation of a chimeric VLP harbouring VP1 of serotype O that is less acid sensitive and which 
successfully induced an immune response in guinea pigs with similar efficacy to the standard FMDV 
inactivated vaccine (Li et al. 2016) 
 
1.4.4 Mammalian cell culture expression system 
Mammalian cell culture expression platforms similarly present a eukaryotic expression system 
capable of the appropriate post-translational modifications, identical to that of the cellular 
environment of the natural virus host in the case of FMDV. This platform was used to successfully 
produce empty capsid VLPs in human embryonic kidney cells/ 293-6E cells (Mignaqui et al. 2013). 
This same study reported that the 293-6E cells achieved similar levels of expression to those 
currently achieved in operating vaccine production facilities with baby hamster kidney-21 (BHK-21) 
cell suspensions infected with live FMDV. Furthermore, it was reported that the transiently 
expressed capsid particles were recognised by serum from vaccinated cattle, and also induced an 
immunogenic response in mice equal to that induced by the same amount of inactivated virus, 
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which had been sufficient to surpass a viral challenge. The study demonstrated the technical viability 
of using empty capsid VLPs, transiently expressed in mammalian cell culture, as a next generation 
FMDV vaccine. Mammalian cell culture is however expensive, limiting the technology’s potential for 
broader industrial application as a more cost effective alternative to that of bacterial cultures, insect 
cell culture or plant expression systems. The authors argue that the use of serum-free suspension-
growing 293-6E cells makes the technology inexpensive, but this is in the context of comparison with 
the current method of FMDV vaccine production which typically uses suspension growing BHK21 
cells. (Mignaqui et al. 2013) 
 
1.4.5 Expression in plant systems  
Plant expression systems have gained much recognition as platforms for expressing recombinant 
proteins (Rybicki 2009; Rybicki 2010). The plant expression platform presents many advantages over 
other expression platforms, particularly insect and mammalian cell culture expression systems, with 
the main advantage being the low cost and ease of upscaling production. A plant, being autotrophic, 
essentially requires primarily carbon dioxide, sunlight, and water, sources of nitrogen and 
phosphorous. These are inexpensive or freely available. It does not require expensive sugar based 
media substrate for growth and protein expression. Using a plant expression system is thus 
competitively advantageous on a financial basis, over the other protein expression systems 
discussed. Plant expression systems do not require the expensive media substrates for the 
production of recombinant proteins that are required by these alternative platforms. Plant based 
recombinant protein expression thus provides a promising, financially viable means of large scale 
production for industrial application ( Sainsbury & Lomonossoff 2008; Rybicki 2009; Regnard et al. 
2010).  
One of the major shortcomings of a bacterial expression platform, as discussed previously, is the 
failure to produce the correct post-translational modifications of recombinant proteins native to 
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eukaryotic cells, as bacteria lack the same mechanisms of protein glycosylation and folding. 
Consequently, many recombinant proteins of eukaryotic origin, expressed in bacterial systems, do 
not present the correct tertiary and quaternary structures, as well as chemical properties, identical 
to the original protein. A plant system, by comparison, is eukaryotic and therefore does not have this 
same disadvantage; on the contrary many heterologous proteins expressed in plants are nearly 
identical to the original proteins (Kushnir et al. 2012). As a consequence of this, the plant expression 
platform is capable of producing VLPs, as these require specific conformational arrangement of the 
constituent proteins (Scotti & Rybicki 2013; Chen et al. 2012). This is particularly favourable since 
VLPs present a highly efficient vaccine approach (Kushnir et al. 2012). The full extent of the potential 
economic advantages of using a plant based expression system for the production of recombinant 
proteins has been comprehensively reviewed(Nandi et al. 2016) and provides a compelling argument 
for the use of the technology in the future of vaccine development and production. 
A plant expression system provides a highly rapid production platform for the expression of 
heterologous protein; these proteins can be expressed at high quantities to accumulate at high 
levels, alternatively they can also be secreted owing to the endomembrane system and secretory 
pathways present in plants (Lico et al. 2008). 
Another significant advantage to using a plant expression system in the context of vaccine 
production (and other products destined for human and/or animal use), is that it is free of 
mammalian pathogens (Kushnir et al. 2012). 
The use of plant expression systems for the production of FMDV proteins has already gained 
significant attention, and consequently is being intensively explored. Initial research efforts focused 
on a transgenic approach whereby the actual genome of the plants would be altered to introduce 
the exogenous recombinant protein genes. Transgenic Arabidopsis thaliana leaf extract containing 
VP1 has been used to elicit a protective antibody response in immunized mice (Carrillo et al. 1998). 
Mice have also demonstrated protection against the virus after receiving vaccinations with leaf 
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extract from inoculated N. benthamiana (Wigdorovitz & Pe 1999) and transgenic alfalfa containing 
VP1 (Escribano & Borca 1999). Similarly the gene for the P1 polyprotein was expressed in transgenic 
alfalfa (Dus Santos et al. 2005). Guinea pigs have been vaccinated with tomato plant produced FMDV 
antigens derived from expression of the P12A gene, and then demonstrated full protection against a 
viral challenge with FMDV (Pan et al. 2008). More recently, however, the focus of most research has 
shifted to investigating transient expression in plants, since this approach is not complicated with 
growing multiple generations, and can produce the recombinant proteins far more rapidly: transient 
expression employs transformed Agrobacteria tumefaciens to transfect plant cells and thereby 
induce expression of with the desired recombinant genes. Recombinant protein will be produced 
within a few days of infiltration, instead of waiting several weeks for transgenic plants to grow 
sufficiently for protein production. VP1 and VP4 epitopes of FMDV have already been successfully 
expressed in the plant expression system Nicotiana benthamiana as a potential candidate vaccine, 
which successfully induced an immunogenic response in guinea pigs (Andrianova et al. 2011). The 
same system has successfully produced FMDV VLPs (Veerapen et al. 2018). VLPs for other viruses, 
including the human papillomavirus have also been successfully produced through the plant 
expression system N. benthamiana. This promising new technology for the rapid production of 
recombinant proteins is still in its infancy – few commercial operations have adopted and 




1.5 Project aims 
The aim of this project was twofold:   
 To generate anti-P12A antibody used as a reagent for detection purposes of recombinantly 
expressed FMDV P12A.  This was carried out by cloning FMDV P12A in an E. coli expression 
vector, purifying expressed P12A and injecting rabbits with it to yield serum for use as the 
detection reagent.  
 To compare the expression of FMDV P12A-3C in Nicotiana benthamiana using 3 different 
plant expression vectors and determine whether VLPs could be assembled with the 
expressed protein. FMDV P12A-3C was cloned into pEAQ-HT, pTRAc, and PRIC3.0 
expression vectors. The gene for the FMDV capsid proteins was cloned into these 
respective vectors which were then used to transform Agrobacteria tumefaciens for 
transfection and expression of recombinant protein in plant leaf cells. Plant leaves were 





Bacterial Expression of FMDV P12A in E. coli 
 
2.1 Overview 
The well characterised method of recombinant protein expression in bacteria is the most well-
established of the different expression systems. The rapid expression afforded by the fast growth of 
the bacteria contributes to the appeal of this expression system. Additionally; the refined motifs 
within available vector plasmids, which enable the specific induction and strict regulation of 
expression, further contribute to the favourability of this expression system for pharmaceutical 
industrial application. Non-hydrolysable lactose analogue isopropyl-β-D-1-thiolgalactopyranoside 
(IPTG) can be used to induce expression via the lac, trc, and tac promoters. These promoter regions 
are located in the region immediately prior to the multiple cloning site (MCS) of the pProEX vector 
(Figure 2.1) allowing for inducible expression of genes cloned into the vector at a position within the 
MCS. The lac promoter is relatively weak and is not particularly effective for protein production at 
high levels, but the neighbouring trc and tac promoters are strong synthetic promoters capable of 
very efficient expression and high levels of protein accumulation (Terpe 2006). T7 RNA polymerase 
delivers far more rapid transcription elongation of mRNA than E. coli RNA polymerase, further 
enhancing the rate of protein expression (Terpe 2006). The gene for T7 RNA polymerase is itself also 
under the control of the L8-UV5 lac promoter and is thus also induced by IPTG; ensuring that the 
entire expression system is strictly and synergistically regulated by the addition of IPTG. 
In the present study, the lactose analogue IPTG was used for the activation of the lac promoter to 
induce P12A expression. After the lac promoter and immediately prior to the MCS, the pProEX 
vector includes a gene that translates to a short peptide sequence of 6 histidine amino acid residues 
followed by a space linker motif of amino acid residues that are expressed with the inserted gene. 
This feature of the pProEX vector means the E. coli expresses the recombinant protein with a His-tag. 
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The His-tag enables the produced protein to be purified with Nickel tagged affinity resin, and also 
enables the protein to be detected using anti-his antibodies. 
The main objective of this project was to express FMDV type A1 capsid proteins in a plant system for 
the purpose of VLP production. However, we had no continual supply of any commercial, or other, 
antibodies specific for FMDV Type A1 in order to use for the detection of recombinant proteins to 
confirm their expression. To address this matter, this project also included an endeavour to produce 
the P12A oligopeptide in the E. coli bacterial expression system with the use of the pProEX vector, 
and to develop a purification protocol in order to ultimately develop antiserum in rabbits against 
FMDV P12A.  
  
Figure 2. 1. pProEX HTa vector map, illustration position 
of lac and trc promoter regions before the MCS. 
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2.2 Materials and Methods 
A Nicotiana . codon optimised version of the FMDV A/Arg/01 (serotype A, Argentinian 1) P12A gene 
sequence, with the gene for the 3C protease incorporated at the 3’ terminus of the sequence of the 
sequence (P12A3C), was synthesized and cloned into pUC57 by GenScript (Inc) USA.  
 
2. 2.1 PCR amplification of P12A fragment  
E. coli containing the pUC 57-P12A3C plasmid were cultured in Luria-Bertina broth (LB) with 
ampicillin (100 µg/mL) at 37 °C overnight. DNA necessary for amplification was extracted using the 
plasmid preparation QIAprep Spin “Miniprep Kit” (QIAGEN) according to the manufacturer’s 
instructions. 
Forward and reverse nucleotide primers were designed for the select amplification of the 2767 bp 
P12A fragment of the gene received from GenScript, excluding the 3C protease gene. The binding 
site of the reverse primer was located prior to the portion of the gene encoding the 3C protease thus 
ensuring amplification excluded the 3C protease, schematically illustrated with green markers in 
Figure 2.2 (entire DNA sequence with primer binding annotation in appendix A).  
These primers were designed to incorporate NcoI and XhoI restriction endonuclease cleavage sites 
(highlighted in blue, Table 2.1. Primers designed for amplification of P12A gene fragmentPCR with 
Phusion® Taq polymerase (New England BioLabs) was used for high fidelity amplification of this 
fragment in order to clone it into the E. coli expression vector pProEX - HTa (Life Technologies, 
Ontario, Canada). Reaction volumes and PCR parameters for gene amplification are detailed in 
Tables 2.2 and 2.3, respectively. The PCR product was run on a 0.8 % (w/v) agarose gel at 120 V for 
45 min to verify that the reaction had generated a fragment of the appropriate size.  
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Table 2.1. Primers designed for amplification of P12A gene fragment. Position of added endonuclease restriction site 
highlighted in blue. 
 Orientation 5’-3’ Nucleotide sequence Restriction site added 
PPX-P12A-F  forward ttc/catgggagcaggtcaatcaagt NcoI 
PPX-P12A-R  reverse ctgac/tcgagttatgggttagattc XhoI 
Screening Reverse caagtttgtgaagatgaccgaaag - 
 
Table 2.2. PCR components and volumes for 50 µL reactions 
Component Volume in 50 
µL Reaction 
Final Concentration 
5X Phusion HF Buffer 10 µL 1X 
10 mM dNTPs  1 µL 200 µM 
10 µM PPX-P12A-F 
Forward Primer  
2.5 µL 0.5 µM 
10 µM PPX-P12A-R 
Reverse Primer 
2.5 µL 0.5 µM 
pUK57-P12A3C DNA 2.5 µL  250 ng 
Phusion® DNA  
Polymerase 
0.5 µL 1.0  
Nuclease-free water 31 µL   
 
Table 2 3. PCR step parameters 
PCR step Initial 
Denaturation  
Denaturation Annealing Extension Final 
Extension 
Hold 
Temp (°C) 98 98 68 72 72 4 
Duration 30 sec 10 sec 30 sec 3 min 10 min  




2.2.2 Cloning of P12A into pProEx HTa E. coli expression vector 
E. coli cells harbouring the empty pProEX HTa vector were grown in 10 mL LB containing ampicillin 
(100 µg/mL) at 37 °C with shaking overnight. DNA for the pProEX vector was extracted from E. coli 
cells using the DNA extraction miniprep kit (QIAGEN) as per the manufacturer’s instructions. 
Amplified P12A and extracted vector DNA were digested using the restriction endonuclease enzymes 
NcoI and XhoI (Thermo Fischer Scientific). Reactions were incubated at 37 °C for 1 hour. Correctly 
linearized pProEX DNA was separated by electrophoresis on a 0.8 % (w/v) agarose gel, at 100 V for 1 
hour. The DNA was retrieved from the agarose gel using a gel extraction kit (QIAGEN) as per the 
manufacturer’s instructions. The DNA was dephosphorylated with Shrimp Alkaline Phosphatase 
(New England Biolabs) prior to the ligation reaction using T4 DNA ligase (Thermo Fischer Scientific). 
Competent DH5α E. coli cells (Lucigen) were transformed with successfully cloned recombinant 
pProEX - P12A plasmids by means of heat shock. Recombinant plasmid DNA and competent cells 
were placed in the same reaction tube and placed on ice for 2 minutes before being placed in a 37 °C 
water bath for 1 minute then returned to ice. Three hundred microlitres (300 µL) LB media was 
added to the reaction tube and the tube was returned to 37 °C water bath for 1 hour. After 1 hour, 
transformed cells were centrifuged in a benchtop centrifuge (Eppendorf 5424) at 17933.4 × g for 5 
minutes. Two-hundred µL of the supernatant media was removed from the tube and the cells were 
re-suspended in the remaining 100 µL. Fifty microliters (50 µL) of transformed cells were plated onto 
Luria agar containing ampicillin (100 µg/mL). The plates were incubated overnight at 37 °C.  
An additional nucleotide primer was designed to amplify a 500 bp internal fragment of the inserted 
gene for the purpose of screening transformed bacterial colonies (identified by a green arrow, Figure 
2.3). Random E. coli colonies were selected from the agar plates and screened by PCR amplification 
of the internal gene specific 500 bp fragment, using ppx-p12a-f and screening primers, to confirm 
successful transformation (colony PCR). Positively transformed colonies were then used to inoculate 
10 mL LB media and incubated at 37 °C with shaking overnight. DNA was again extracted from the 
E.coli using the miniprep extraction kit (QIAGEN). A double restriction digest, with XhoI and NcoI 
23 
 
enzymes, of the DNA retrieved from the E.coli transformed with pProEX-P12A, further verified that 
the E. coli had been successfully transformed with the recombinant pProEX - P12A plasmid. Aliquots 
of transformed E. coli containing the pProEX - P12A plasmids were stored at -80 °C in a 50 % glycerol 
solution. 
DNA fragments generated through cloning and PCR procedures were run on agarose gels for the 
purpose of visualising the experimental results. Four microliters of ethidium bromide (0.1g/mL) were 
added to 100 mL agarose gels, in order to visualise the DNA when viewed under UV light. Gels were 
photographed with short wavelength (280 nm) UV-B light. 
  
Figure 2.3. Schematic diagram of cloned pProEX – P12A construct with labelled PCR amplified insert and relevant restriction 








2. 2.3 P12A induced expression 
After successfully transformed E. coli were verified by means of colony PCR and restriction enzyme 
digests, for the recombinant pProEX - P12A plasmids, 10 mL volumes of Luria broth media (LB) were 
inoculated with 1 mL glycerol stock of transformed E. coli and cultured at 37 °C with shaking 
overnight for protein expression. IPTG was added to a final concentration of 0.6 mM once the 
culture had reached an optical density of between 0.5 and 1. A time trial was conducted to establish 
the amount of time necessary for optimal protein expression; 1 mL samples were removed from the 
culture, prior to induction by addition of IPTG, and every hour for 3 hours post the addition of IPTG. 
Cells were pelleted with a benchtop centrifuge at 17933.4 × g for 2 minutes, the supernatant was 
discarded and the cells re-suspended in 200 µL Phosphate buffered saline (PBS) for protein 
extraction. 50 µL 5 × sample application buffer (SAB), (composition detailed in appendix C), was 
added to the cell re-suspension and samples incubated at 95 °C for 10 minutes to denature proteins 
prior to analysis by SDS-PAGE and western blot. 
 
2.2.4 Protein analysis by SDS PAGE, Western Blot, Coomassie Blue stain 
10% SDS Polyacrylamide gels were made up as described in appendix B. Thirty microliters (30 µL) of 
protein samples prepared in section 2.2.3 were loaded in gel wells, one lane was loaded 5 µL NEB 
Broad range protein marker ladder. Gels were submerged in 1 × running buffer (composition of 10 × 
concentrated running buffer detailed in appendix B) for electrophoresis and run at 120 V for ≥2 h 
using Bio-Rad equipment. 
For western blotting, the gels were placed on nitrocellulose membranes pre-soaked in transfer 
buffer (composition detailed in appendix B), which were sandwiched between blotting paper also 
soaked in transfer buffer. The blot sandwich was transferred at 15V for ≥ 2h using a transblotter 
(Bio-Rad). After transfer the membrane was washed in blocking buffer (+ 5 % m/v fat-free milk 
powder in 1 × PBS, composition detailed in appendix B) with shaking for 30min at room 
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temperature. The membrane was probed with guinea pig or rabbit anti FMDV antibodies (kindly 
donated by Andrés Wigdorovitz, INTA, Buenos Aries) diluted 1 in 100 in blocking buffer (+ 5% m/v 
fat-free milk powder in 1 × PBS), and incubated at 4 °C with shaking overnight. The membrane was 
then washed with blocking buffer four times for 15 min. After washing the membrane was probed 
with alkaline-phosphatase-conjugated anti-guinea pig/ rabbit secondary antibody, diluted 1 in 10 
000 in blocking buffer for 1 hour at 37 °C, after which the membrane was again washed with 
blocking buffer lacking milk four times for 15 min. The blot was developed with 3 mL BCIP/NBT 
(Sigma-Aldrich) for 1 h. 
Polyacrylamide gels used for Coomassie staining, instead of western blotting, were placed in 
Coomassie blue stain solution (appendix B) after electrophoresis, and left shaking at room 
temperature overnight. Coomassie blue stain solution was discarded and replaced with de-stain 
solution (appendix B) and the gel was left shaking in de-stain solution, until protein bands had 
become distinct. 
 
2.2.5 Scaled up induction of P12A expression 
Overnight cultures of recombinant E. coli were used to inoculate fresh 100 mL volumes of LB media. 
Cultures were grown at 37 °C with shaking until the optical density reached between 0.5 and 1.0, at 
which time IPTG was again added to a final concentration of 0.6 mM to induce the expression of 
P12A. The culture was incubated at 37 °C with shaking for 3 hours. After 3 hours the culture was 
centrifuged at 10 000 ×g (Beckman Coulter centrifuge) for 10 minutes, the supernatant was 
discarded and the pellet was stored at – 80 °C. In order to determine whether the expressed P12A 
was soluble or insoluble, 100 µL samples of the stored cells were transferred to a clean Eppendorf 
tube and re-suspended in 1 mL lysis buffer (QIAGEN). To achieve cell lysis, the re-suspended cells 
were sonicated at 14 µm amplitude for 1 minute. The suspension was centrifuged at 17933.4 × g for 
2 minutes to pellet the cell debris. The supernatant was transferred to a clean Eppendorf tube this 
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was the soluble fraction; the cell pellet that remained was re-suspended in another 1 mL of lysis 
buffer – this was the insoluble fraction. To each of the 100 µL fractions 25 µL of 5 × SAB was added, 
and denatured at 95 °C for 10 minutes. The samples were analysed by SDS-PAGE and western blot as 
described in 2.2.4. After confirmation that the expressed protein was insoluble, cell lysis of the 
remaining stored pelleted cells was performed using the Bug Buster® (Novogen) protocol. These 
cells were re-suspended with 5 mL of Bug Buster® reagent per gram of cells. Benzonase® nuclease 
was added to the buffer at 1 µL per mL. Lysozyme was added at 1000 units per mL of buffer. The re-
suspended cells were incubated at 4°C with shaking for 30 minutes, and the cell suspension was then 
centrifuged at 16000 ×g for 20 minutes – the supernatant (soluble fraction) was discarded. A portion 
of the pellet was re-suspended in 100 µL of 1 x PBS and denatured with 25 µL of 5 × SAB at 95 °C for 
10 minutes to represent the unpurified protein sample when analysed by western blot and SDS-
PAGE. Purification of the protein inclusion bodies was performed using the Bug Buster® protocol as 
per its instructions. The final pellet was again re-suspended in PBS with 0.1 % Triton, in a volume 
equal to that of 1/10th of the original culture volume. The suspension was centrifuged at 16000 ×g 
at 4 °C for 10 minutes to collect inclusion bodies. Re-suspension and centrifugation of the inclusion 
body pellet was repeated five times, and the final pellet was re-suspended in 2 mL of PBS with 0.1 % 
Triton. 25 µL of 5 × SAB were added to 100 µL of the sample and denatured at 95 °C for 10 minutes 
prior to analysis by SDS-PAGE and western blot as described in 2.2.4. 
 
2.2.6 Purification of P12A using affinity chromatography 
Immobilized metal affinity chromatography, with Nickel chelate (Ni-NTA) (Sigma-Aldrich) resin 
columns, was used in an attempt to further purify the protein inclusion bodies. Pelleted inclusion 
bodies were re-suspended in 14 mL denaturing equilibration buffer (DEB(appendix B)) containing 
two protease Inhibitor tablets (cOmplete™, Mini, EDTA-free, Sigma-Aldrich). The suspension was left 
to shake for 10 minutes and then centrifuged at 8595.3 × g in a benchtop centrifuge for 10 minutes. 
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The supernatant was discarded and the pellet re-suspended in 2 mL DEB prior to being run through a 
pre-equilibrated column and collecting the flow-through. The column was then washed with three 
column volumes of washing buffer (appendix B) and then three 1 mL fractions of washing buffer, 
each fraction was collected. Four 1 mL fractions of elution buffer (appendix B) were then run 
through the column and elution fractions collected. 100 µL of each fraction sample was denatured 
with 25 µL of 5 × SAB at 95 °C for 10 minutes for analysis by SDS-PAGE and western blot as described 
in 2.2.4. 
In an effort to resolve poor binding of expressed P12A to Ni-NTA resin, treatment with 8 M urea was 
used to solubilize the inclusion bodies. The pelleted inclusion bodies were resuspended in 8 M urea, 
vortexed and left shaking for 15 minutes. The suspension was centrifuged at 16000 ×g at 4 °C for 10 
minutes. The final pellet was again re-suspended in PBS with 0.1 % Triton and the suspension was 
again centrifuged at 16000 ×g at 4 °C for 10 minutes. Re-suspension and centrifugation of the urea 
treated pellet was repeated 5 times, and the final pellet was re-suspended in 2 mL of PBS with 0.1% 
Triton prior to metal affinity chromatography. 
Persistent absence of any detectable P12A protein band from metal affinity chromatography 
required a cognate anti-his blot to clarify whether the lack of P12A was possibly due to cleavage of 
the his tag, in which case the six histidine residue tag might have been binding successfully to the 
resin, but without P12A which was being probed for with anti-FMDV antibodies. 
This protocol was adapted by fellow student Varusha Veerapen for the production and purification 
of the P12A oligopeptide to obtain amounts sufficient to inject into rabbits for the generation of anti 
– P12A rabbit anti serum capable of detecting both the E. coli produced P12A and the plant 







2.3.1 PCR amplification of P12A and restriction enzyme digest of pProEX  
The pProEX plasmid was successfully digested with NcoI and XhoI evident from the 4663 bp band 
visible in Figure 2.4 (lane 1). P12A was successfully amplified from pUC57 - P12A3C and digested 













≈ 2276  bp 
≈ 4779  bp 
5000 bp 
≈ 4663  bp 
Figure 2.4. pProEX  Digested with NcoI and XhoI(4663 bp) lane 1; PCR 
amplified P12A fragment (2276 bp) lane 2, digested with NcoI and XhoI ; 
pProEX linearized with NcoI lane 3 (4779). 
1 2 3 
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2.3.2 Cloning of P12A into pProEX and transformation 
Successful cloning of the P12A gene fragment into the pProEx vector plasmid, and subsequent 
transformation of the pProEX-P12A construct into E.coli was verified by colony screening PCR and 
restriction enzyme digest. Figure 2.5 shows that 3 of 8 colonies screened with primers to generate a 
500 bp band were positive. Gels showing restriction enzyme digest of colony 1 (Figure 2.6) showed 
fragments with the appropriate sizes for the insert (2276 bp) and vector (4663 bp) as opposed to the 
empty vector which only displayed a single band (4779 bp), therefore further confirming that the 
ligation and cloning of the insert into the vector had been successful. 
 
  
Figure 2.6. Restriction endonuclease linearization of pProEX-P12A using restriction 
enzyme XhoI (lane 1); double digestion of pProEX-P12A using restriction enzyme XhoI & 
NcoI (lane 2) linearization of pProEX-empty using restriction enzyme XhoI (lane 5); double 
digestion of pProEX-empty using restriction enzymes XhoI & NcoI (lane 6).  
Figure 2.5. pProEx-P12A colony PCR amplification of 500 bp fragment with internal 
screening primer. Lanes 1 – 8 randomL y selected colonies from agar plate. Lane 9 = 
negative control colony with empty pProEX.Ladder used = O’GeneRuler™ 100 bp Plus 
1 2 3 4 5 6 7 9 8 







2.3.3 Induced expression of P12A with IPTG 
The expression of P12A was successfully induced with IPTG. Western blot analysis of the samples 
obtained from the protein expression time trial (Figure 2.7) showed the most prominent band in the 
region of the expected 81kDa P12A peptide in the lane corresponding to the sample taken 3 hours 
post induction. The blot indicates that the best levels of expression were achieved at least 3 hours 
post induction with IPTG, although low levels of expression were already evident in the sample taken 


























Figure 2.7. Western blot of P12A ≈ 81kDa, indicated by an arrow, induced expression time trial in E. coli probed with 
Guinea pig anti-FMDV antiserum. Positive control shows VP1/VP3, indicated by an arrow. 
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2.3.4 Protein purification of up scaled expression 
Having established that the highest level of expression occurred 3 hours post infiltration, tests were 
carried out to determine whether the expressed protein was soluble or insoluble. P12A was 
detected in both soluble and insoluble fractions. Western Blot analysis revealed the more prominent 
(darker) band of 80 kDa in the lane corresponding to the sample of the insoluble fraction (Figure 
2.8).  
The western blot of the purified inclusion bodies showed a distinct prominent band of approximately 
81 kDa (Figure 2.9). The insoluble fraction was concentrated further by repeated washes with 
BugBuster™ reagent and then PBS, results of which are shown in figure 2.10. The 80 kDa band is 








Figure 2.9. Western blot of gel comparing purified 
inclusion bodies of insoluble P12A indicated with 
arrow, expressed in E.coli, via pProEX, induced with 
IPTG. Lane 1 = pProEX-empty purified inclusion bodies; 
lane 2 = pProEX-P21A purified inclusion bodies; Ladder 









fraction FMDV +ctrl 
Figure 2.8. Western blot comparing samples of pProEX-empty soluble protein 
extract (lane 1), pRoEX-P12A soluble protein extract (lane 2), pProEX-empty 
insoluble protein extract (lane 3), pRoEX-P12A insoluble protein extract (lane 4), 




cells   
P12A purified 
Inclusion 
bodies Wash 2 Elution 1 Wash 1 Elution 2 
Figure 2.10. Western blot of gel comparing purified inclusion bodies of insoluble P12A, indicated with arrow, expressed in E.coli, via pProEX, inuced 
with IPTG. Lane 1 = pProEX-empty pre-induced; lane 3 = pProEX-crude lysed cells; lane 4 = pProEX-P12A purified inclusion bodies; lane 5 = Wash 







An attempt to further purify the protein was made with Nickel affinity chromatography using Ni-NTA 
resin columns to bind the His-tagged P12A protein of the insoluble fraction. However, no P12A band 
of 81 kDa was evident in the elution fractions (Figure 2.10). The hydrophobic nature of the inclusion 
bodies is likely a significant factor contributing to the resin’s inability to bind the protein. To address 
the possibility that the hydrophobic nature of insoluble protein in the inclusion bodies was hindering 
binding to the resin, the P12A protein was treated with 8 M urea prior to chromatography in order 
to solubilize the protein so that it might increase binding with the  Ni-NTA resin. This proved to be 
unsuccessful. No band corresponding to the 81 kDa size of P12A could be seen in the elution 
fractions (Figure 2.11). This was not resolved despite treatment with 8 M urea intended to solubilize 
the expressed P12A (Figures 2.10, 2.11, 2.13). Instead, the first wash fractions showed a band of the 
appropriate size indicating that the protein was still not binding to the Ni-NTA resin effectively and 
was being lost in both the flow-through and wash fractions.  
The western blot was repeated; Anti-His antibodies were used for the primary antibody probe as an 
alternative to anti-FMDV antiserum (Figures 2.12) in order to verify that the results observed were 
not in fact caused by cleavage of the His-tag. The blot revealed the same P12A band in the 81 kDa 
region of the wash and flow through fractions as did the anti-FMDV primary antibodies, but not the 
elution fractions, dispelling the possibility that the His-tag at the N terminus of the protein had been 
























P12A 80 KDa 
Figure 2.12. Western blot with anti-His 1 ̊antibodies, of gel comparing purified inclusion bodies of insoluble P12A expressed in E.coli, via pProEX, 
inuced with IPTG for 3 h.The expressed pritein was purified with BugBuster inclusion body purification protocol followed by 8M urea denaturation 
and NTA resin column purification. Lane 1 = pProEX-empty pre-induced; lane 3 = pProEX-P21A purified inclusion bodies elution 2; lane 4 = pProEX-
P21A purified inclusion bodies elution 1; lane 5 = pProEX-P21A purified inclusion bodies Wash 1; lane 6 = Flow through; lane 7 = solubilized 
Inclusion bodies with 8M Urea; lane 8 = re-suspended pellet from 8M urea treatment; lane 9 = BugBuster purified Inclusion bodies; lane 10 = 



















P12A 80 KDa 
Figure 2.11. Western blot with anti-FMDV 1̊ antibodies, of gel comparing purified inclusion bodies of insoluble P12A expressed in E.coli, via 
pProEX, inuced with IPTG for 3 h. The expressed protein was purified with BugBuster inclusion body purification protocol followed by 8M urea 
denaturation and NTA resin column purification. Lane 1 = pProEX-empty; lane 3 = pProEX-P21A purified inclusion bodies elution 2; lane 4 = 
pProEX-P21A purified inclusion bodies elution 1; lane 5 = pProEX-P21A purified inclusion bodies Wash 1; lane 6 = Flow through; lane 7 = 
solubilized Inclusion bodies with 8M Urea; lane 8 = re-suspended pellet  from 8M urea treatment; lane 9 = BugBuster purified Inclusion bodies; 
lane 10 = Soluble fraction from initial extraction. Ladder used = NEB #P7712S boad range protein marker. 
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2.4 Discussion  
The gene for the P12A oligopeptide was successfully cloned into the pProEX expression vector which 
was subsequently transformed into competent E. coli for protein expression. Induction of the 
recombinant E. coli with IPTG resulted in P12A expression after 1 to 3 hours, visualised as an 80 kDa 
sized protein band on western blots. The highest observed expression was after 3 hours induction 
and this time was subsequently used for further expression. Although P12A was present in both 
soluble and insoluble fractions of the cells, the higher levels appeared to be in the insoluble fraction, 
and so further work was carried out with this fraction. The insoluble fraction was repeatedly washed 
with BugBuster™ Protein Extraction Reagent and PBS in efforts to increase the concentration of 
P12A by removing impurities.  
Further attempts to purify P12A with Ni-NTA resin were unsuccessful. This was not surprising. The 
protein was from the insoluble fraction and the resin is known to have poor binding with insoluble 
proteins. Insoluble proteins have hydrophobic chemical groups exposed, and the charged histidine 
groups are inaccessible to the nickel chelating complex of the resin. The challenge of recombinant 
protein aggregating into inclusion bodies, as a consequence of incomplete protein folding, when 
expressed with E.coli is frequently encountered (Singh et al. 2015). 
Consequently, treatment with 8 M urea was used in an attempt to solubilize the insoluble P12A 
protein so that it might bind to the resin. Urea is a widely recognized denaturing agent aiding 
solvation of proteins through stabilizing peptide and non-polar groups, thereby denaturing the 
proteins by decreasing hydrophobic effects and forming hydrogen bonds, binding with amide groups  
(Wei et al. 2010; Zou et al. 1998; Duke & Carolina 1963). Urea treatment however also proved 




Plant expression and yield quantification of FMDV structural proteins 
and VLP formation 
3.1 Overview 
In the past, virus-like particles (VLPs) of FMDV serotype O and Asia 1 have been successfully 
expressed with a baculovirus expression system (Li et al. 2016; Mohana Subramanian et al. 2012; 
Cao et al. 2009). Other expression systems have also been used to express FMDV VLPs such as 
silkworm larvae (Li et al., 2012), E. coli (Lewis et al., 1991; Xiao et al., 2016), insect cells (Cao et al., 
2009; Porta et al., 2013b; Roosien et al., 1990), mammalian cells via recombinant vaccinia virus 
(Abrams et al., 1995) and in transfected mammalian cells (Mignaqui et al., 2013). In addition to 
these, various FMDV structural proteins and VLPs have been expressed in plants as an expression 
system. These include transgenic alfalfa plants and tomato fruits (Dus Santos et al., 2005; Dus Santos 
and Wigdorovitz, 2005).Carrillo et al. (1998), document the expression of FMDV structural protein 
VP1 in transgenic Arabidopsis thaliana, the earliest account of a virus antigen expressed in a 
transgenic plant, conferring protective immunity. This was used as a subunit vaccine to immunize 
mice against virulent FMD. In a similar fashion, the polyprotein VP1 with the 3C protease was 
expressed in transgenic Alfalfa, and also induced a protective immune response in mice (Dus Santos 
et al. 2005). Polyepitope proteins including B-cell epitopes of FMDV VP1 and VP4 with T-cell epitopes 
from 2C and 3D proteins, have also been successfully expressed in E. coli and N. benthamiana, and 
demonstrated to induce an efficient immune response in guinea pigs (Andrianova et al. 2011). In 
addition, Veerapen et al. (Veerapen et al. 2018) showed the expression of FMDV structural proteins 
and VLP assembly using transient expression mediated by agroinfiltration of a recombinant plant 
expression vector. However, yields of VLPs were low. 
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The primary objective of this project was to compare the transient expression of FMDV structural 
proteins and VLP formation in N. benthamiana using two additional plant expression vectors.to 
determine whether the VLP yield could be increased. The three different plant expression vectors; 
pEAQ-HT, pTRAc, and pRIC3.0 (schematically illustrated in Figure 3.1) have distinguishing features: 
the pEAQ-HT vector allows for the easy and quick expression of recombinant proteins in plants and 
is based on the Cow Pea Mosaic Virus derived from pBINPLUS but with over half of the vector 
backbone removed. The reduced size of the vector can be transcribed and translated more quickly, 
thereby greatly improving yields (Sainsbury et al. 2009); pTRAc by contrast is a plant expression 
vector created using the Cauliflower Mosaic virus (CaMV) 35S promoter and to improve expression 
of foreign genes it includes duplicated transcriptional enhancer chalcone synthase 5’ UTR and CaMV 
35S polyadenylation signal (Maclean et al. 2007); pRIC3.0 was created from the pTRAc backbone 
with the incorporation of intergenic regions based on the Bean Yellow Dwarf Virus (BeYDV), which 
creates DNA replicons containing the inserted gene that can be transcribed and thus translated 
independently, thus providing higher expression (Regnard et al. 2010).  
The principle of this approach to create a vaccine candidate, was to introduce the P12A3C gene 
encoding the FMDV structural proteins into N. benthamiana plants via Agrobacterium- mediated 
transformation of the recombinant vectors by infiltration. The significance of incorporating the 3C 
protease is that it facilitates cleavage of the P12A oligopeptide into component structural proteins: 
VP0, VP1, and VP3, necessary for VLP formation; whether this also happened with expression via the 
pTRAc vector was of particular interest in this project. Infiltrated plant leaves were harvested several 
days post infiltration and screened for FMDV protein expression.  
 
3.2 Materials and methods 
The methods are summarised in a stepwise procedure presented in the Work-Flow chart 3.1 at the 
end of the section (Pg 46).  
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3.2.1 Cloning of recombinant plant expression vector pTRAc-P12A3C 
The same Nicotiana. codon optimised P12A3C (section 2.2), was cloned into the pTRAc plant 
expression vector (Maclean et al. 2007) for expression of the FMDV viral capsid proteins in 
N.benthamiana.  
Alternative vector constructs pEAQ-HT-P12A3C and pRIC3.0-P12A3C, were provided by the BRU. The 
vector maps for pTRAc, pRIC3.0 and pEAQ-HT are illustrated in Figure 3.1. 
The XhoI and NcoI restriction enzymes were used for the excision of the gene from the pUC 57-
P12A3C plasmid. NcoI and AflIII, with restriction sites complementary to NcoI and XhoI respectively, 
were used for the digestion linearization of the destination pTRAc vector to generate compatible 
sticky ends for ligation of the vector construct. Since the pTRAc expression vector does not contain 
an NcoI site; AflIII and XhoI restriction enzymes (Thermo Fischer Scientific) were used to linearize the 
pTRAc vector in order to enable the complementary insertion of the P12A3C gene Endonuclease 
restriction digest reactions were performed according to the manufacturer’s instructions (Thermo 
Fisher Scientific) at 37 ˚C for 1 hour.  
DNA fragments were separated by electrophoresis in a 1 % (w/v) agarose gel at 120 V for 1 hour. The 
gel was viewed under longwave UV A light (400nm) to reduce potential damage to the DNA while 
enabling the excision of the DNA bands. The precise portions of gel containing the relevant 2952 bp 
DNA bands were manually excised using a scalpel blade and DNA extracted according to the 
instructions of the QIAquick® Gel Extraction Kit (QIAGEN). DNA was de-phosphorylated with Shrimp 
Alkaline phosphatase (rSAP by New England Biolabs). A ligation reaction was performed to clone 
P12A3C into linearized pTRAc using T4DNA ligase (Thermo Fischer Scientific) to generate pTRAc-











3.2.2 Transformation of pTRAc-P12A3C into E. coli and A. tumefaciens 
The newly constructed pTRAc-P12A3C (Figure 3.2) was transformed into E. coli by heat shock (see 
section 2.3.2). These cells were plated on media containing 100 µg/mL ampicillin and then incubated 
at 37 °C overnight. Transformed E. coli cells were verified by a means of DNA digest reactions using 
endonuclease restriction enzymes EcoRV (Thermo Fischer Scientific) which recognises two restriction 
sites, one of which is situated within P12A3C, and another present in the vector (Figure 3.2) to yield 
two bands of approximately 6.2 kb and 2.9 kb. Colony PCR using the same primers described in 
section 2.3.3 was also performed for confirmation. Transformed E. coli cells from the plate were 
used to inoculate 10 mL LB and grown in culture overnight at 37°C with agitation. Recombinant E.coli 
DNA was extracted using QIAprep Spin Miniprep Kit (QIAGEN), according to the manufacturer’s 
instructions. 
 
Figure 3.2. Schematic diagram of pTRAc-P12A3C vector construct indicating position of EcoRV and XhoI 
endonuclease restriction sites in relation to the gene insert size. 
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Electrocompetent A. tumefaciens cells were prepared by inoculating 100 mL LB containing 30 µg/mL 
kanamycin, and 50 µg/mL rifampicin with 1 mL A. tumefaciens GV3101::pMP90RK and incubated 
overnight at 27 °C with agitation. The 100 mL overnight culture was then centrifuged at 2448.5 × g 
for 10 min to pellet cells. The supernatant was discarded and the cell pellet resuspended in 2 mL 
sterile water, then tubes refilled and re-centrifuged for 10 min at 2448.5 × g. The rinse step was 
repeated, and then the cell pellet was resuspended in 10 % glycerol and washed again as described 
above. The wash with 10 % glycerol was also repeated. The final pellet was resuspended in a volume 
of 5 mL 10 % glycerol. 
Electrocompetent A. tumefaciens GV3101::pMP90RK cells were transformed by electroporation (1.8 
kV; 25 µF; 200 ) with the pTRAc-P12A3C plasmid DNA purified from E. coli. Transformed cells with 
pTRAc-P12A3C were selectively grown on plates of LB media containing kanamycin (50 µg/mL ), 
carbenicillin (100 µg/mL) and rifampicin (100 µg/mL ), then verified by EcoRV endonuclease 
restriction digest and colony PCR amplification using the same screening primers described in 
section 2.2.2 (Table 3.1), with same parameters (Table 3.2). Recombinant agrobacteria were used for 
infiltration of N. benthamiana plants.  
 
Table 3.1. P12A3C screening primers for PCR amplification of 500 bp internal gene fragment 
 Orientation 5’-3’ Nucleotide sequence 
PPX-P12A-F  forward ttccatgggagcaggtcaatcaagt 
P12A-screening R  reverse caagtttgtgaagatgaccgaaag 
 
Table 3.2. Colony screening PCR cycle parameters 
PCR step Initial 
Denaturation  
Denaturation Annealing Extension Final 
Extension 
Hold 
Temp (°C) 95 95 63 72 72 10 
Duration 3 min 30 sec 30 sec 3 min 15 min  




3.2.3 Small scale syringe infiltration of N. benthamiana leaves  
In an attempt to optimise protein expression with the pTRAc-P12A3C vector construct, an optical 
density trial was performed to estimate the best concentration of bacteria to use for infiltration, and 
simultaneously a time trial was conducted to provide some indication of the best time at which to 
harvest leaves for optimal protein expression. Three × 10 mL LBB (composition detailed in appendix 
B) vials were inoculated with 500 µL pTRAc-P12A3C and the cultures grown overnight at 27 °C with 
agitation. Infiltration medium (appendix B) was added to each 10 mL culture to dilute the cultures to 
optical densities (OD600) of 0.25, 0.5 and 0.75. Nicotiana benthamiana plants were infiltrated with 
Agrobacterium suspensions; by injecting into into the abaxial air spaces from the underside of the 
leaf, using a 1 mL syringe and left to grow under conditions of 24°C, 55% humidity and an 16h:8h 
light:dark cycle. Three leaf discs, approximately 1 cm (size of an Eppendorf tube cap) in diameter 
were harvested (closing an Eppendorf tube cap to punch the holes/discs out of the leaves) from 
plants at 3, 4, 5, 6, and 7 days post infiltration. Leaf discs were ground to a fine powder in liquid 
nitrogen using a micro pestle. Protein extraction was performed using 400 µL (PBS) with 0.5 % Triton 
X-100, and one protease inhibitor tablet (Roche EDTA free mini cocktail tablets) (1/10 mL) to reduce 
protein degradation resulting from the release of endogenous protease enzymes during leaf 
processing. Samples were vortexed for 2 minutes then centrifuged in a benchtop centrifuge 
(Eppendorf 5424) at 17933.4 × g for 5 minutes. After centrifugation the supernatant was transferred 
to a clean tube. The soluble proteins were denatured with the addition of 5 × sample application 
buffer (SAB) (appendix B) and incubated at a temperature of 95 °C for 10 minutes. Samples were 
then analysed by SDS-PAGE and western blot, as described in section 2.2.4, with guinea pig or rabbit 
anti FMDV antiserum (kindly donated by Andres Wigdorovitz, INTA, Buenos Aries) diluted 1 in 100 in 
blocking buffer (+ 5 % m/v fat-free milk powder in 1 × PBS), and incubated at 4°C with shaking 




3.2.4 Large scale vacuum infiltration of N. benthamiana 
Large-scale expression involved infiltration of up to 25 plants, approximately four weeks old. For this 
scale of infiltration, 1L volumes of LBB media were inoculated with an 11 mL pre-culture of 
recombinant Agrobacterium strain. Transformed A. tumefaciens contained either pTRAc-P12A3C; 
pRIC3.0-P12A3C, or pEAQ-P12A3C, grown overnight at 27 °C containing respective antibiotics 
(kanamycin, rifampicin and carbenicillin for GV3101 agrobacteria and only kanamycin and rifampicin 
for pEAQ containing LBA4404 Agrobacteria, at concentrations described in section 3.2.2), with 
agitation. The 1 L inoculated culture was also grown overnight at 27 °C and then diluted with 
infiltration medium to an OD600 of 0.5. The plants were infiltrated by vacuum infiltration at -100 kpa. 
Plants were returned to growth rooms to continue growing and allow for expression of the 
heterologous protein. These rooms had the same growing conditions as described above. 
 
3.2.5 Processing of large-scale infiltrated leaves 
Plant leaves were harvested 3 days post infiltration. Sixty grams of plant leaves were homogenised 
with 180 mL of buffer solution, (buffer solution volume (ml) = 3 × leaf mass (g): 1 × PBS (pH 7.0) 
supplemented with 1% Triton-X100 and three protease inhibitor cocktail tablets (Roche), using a 
homogenizer). The homogenous liquid was left to shake at 4 °C for 30 minutes to allow for protein 
extraction. The liquid was then filtered through a double layer of Miracloth™ to remove leaf debris, 
after which it was centrifuged (Beckman Coulter) at 3098.8 × g for 15 minutes, removing any 
remaining cellular debris. The supernatant was pipetted on to a 5 mL cushion of 30 % sucrose (w/v in 
PBS), and centrifuged (Beckman Coulter ultra-centrifuge) at 125755 × g for 3 hours at 20 °C.  
One millilitre fractions were taken from the supernatant, the 30 % (w/v) sucrose cushion, and a 
sample from the pellet respectively, for analysis by SDS-PAGE and western blot as described in 2.2.4.  
The remaining pellet was then re-suspended with 3 mL PBS containing 1 % Triton X-100 and 5 µL 
Benzonase® nuclease, in a mortar with a pestle. The pellet suspension was left overnight at 4 °C 
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allowing time for maturation to promote particle formation before being separated by rate-zonal 
centrifugation.  
 
3.2.6 Sucrose gradient purification of VLPs 
A continuous sucrose density gradient ranging from 5 to 20 % sucrose (w/v) was set up in a volume 
of 34 mL in a 40 mL ultracentrifuge tube. The re-suspended pellet matured overnight was loaded on 
top of the sucrose gradient. A further 2 mL of PBS was used to rinse the mortar of residual pellet 
suspension adhering to the sides, and added to the ultracentrifuge tube, bringing the total volume of 
pellet suspension to 5 mL, once the 5 mL of re-suspended pellet had been laid on top of the sucrose 
gradient, it was centrifuged at 125755 × g for 3 hours. The procedure was repeated, centrifuging the 
pellet suspension through a 15 – 40 % sucrose gradient for 2 hours instead of 3 hours. The gradient 
was fractionated into 1 mL fractions.  
 
3.2.7 Analysis of gradient fractions 
Dot blots were performed with the gradient fractions.  A 2 µL aliquot from each fraction was 
pipetted onto a piece of nitrocellulose membrane. The membrane was washed in blocking buffer 
(appendix B) containing 1 % Tween20 and 5 % (m/v) milk powder for 15 minutes. The membrane 
was then probed with guinea pig anti-FMDV polyclonal antiserum (1:100 dilution), overnight. 
Following the probing with primary antibodies, the membrane was again washed with blocking 
buffer and then probed with alkaline phosphatase conjugated rabbit anti-guinea pig secondary 
antibodies (Sigma-Aldrich) developed in rabbits (diluted 1 in 10000), after which the dot-blot 
membrane was washed and developed over 1 hour with BCIP/NBT substrate (KPL). Those fractions 
that generated the darkest dots were selected for further analysis by SDS-PAGE and western blot 
(performed as described in section 2.3.4).  
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To determine whether expressed proteins assembled into VLPs, transmission electron microscopy 
(TEM) was used for viewing of selected fractions. Glow discharged carbon/copper grids were placed 
on 10 µL of the protein extracts and left for 2 min before being washed 6 times with sterile distilled 
water water. Grids were then floated on 20 µL of 2 % uranyl acetate for 1 min, dried and then 
viewed with a Zeiss 912 OMEGA Energy Filter Transmission Electron Microscope, University of Cape 
Town, to evaluate whether the expressed proteins were able to assemble into VLPs, and hence 
determine the fraction of the gradient in which the VLPs could be found.  
 
3.2.8 Protein quantification 
Fractions containing putative VLPs were also separated by SDS-PAGE together with a standardised 
bovine serum albumin (BSA) dilution series, from 3.13 µg – 0.20 µg, and then stained with 
Coomassie blue in order to quantify the relative amount of the expressed protein by gel 
densitometry. The quantification estimates were performed using SynGene™ computer software, to 
calculate the approximate total protein yield. 
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The FMDV capsid protein genes P12A3C were cloned into the pTRAc expression vector from pUC 57 
Compitent E. coli cells were transformed with recombinant pTRAc-P12A3C by heat shock and grown in culture to 
amplify the quantity of recombinant plasmid DNA.
A. tumefaciens were trasformed by electroporation with recombinant pTRAc-P12A3C DNA amplified and extracted 
from E. coli
Plants were infiltrated with media containing the transformed A. tumefaciens. Syringe infiltration was used for small 
scale (<5 plants) while vacuum infiltration was used for large scale (≥20 plants)
Leaf material was harvested after at least 3 days growth post infiltration.
Harvested leaf material was processed for protein extraction.
Protein extract was purified by ultra centrifugation throgh a sucrose cushion and sucrose gradient.
samples were analysed by SDS-PAGE with western blot and commasie stain, and samples were also prepared on 
grids for TEM viewing. 




3.3.1 Plant expression vector construction – pTRAc-P12A3C 
P12A3C was successfully cloned into the pTRAc plant expression vector to yield pTRAc-P12A3C. The 
construct was successfully transformed into A. tumefaciens pMP90::RK90 as demonstrated by PCR of 
putatively transformed colonies and double restriction digest. Figure 3.3 shows the expected 500 bp 
band amplified from P12A3C insert of all colonies selected. Figure 3.4 shows two bands, of 
approximately 2900 bp and 6200 bp, appropriately sized for the EcoRV double digest of the pTRAc 
containing the P12A3C insert, compared with linearized empty pTRAc of 6107 bp. 
  
Figure 3.4. Restriction endonuclease digestion to linearize pTRAc-P12A3C construct and empty pTRAc with XhoI (lanes 1 & 
2 respectively), and with EcoRV (lanes 3 & 4 respectively. Ladder used = O’generuler 1kb. 
Linearization XhoI digest EcoRV digest 
3000 bp 
6000 bp 
Figure 3.3. Agarose gel electrophoresis showing results of the colony screening PCR amplification of a 500 bp internal gene fragment.  
The presence of  a band verifies successful insertion and subsequent ligation of the pTRAc-P12A3C vector construct. Lane 2 = pTRAc-
empty (negative control); lane 3 – lane 11 = selected colonies 1 – 10; lane 12 = pUC57 storage plasmid of P12A3C (positive control). 
Ladder used = O’GeneRuler™ 100 bp Plus DNA Ladder. 
2 3 4 5 6 7 8 9 10 11 12 
1 2 3 4 
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3.3.2 Syringe Infiltration of pTRAc-P12A3C to assess protein expression 
Small scale syringe infiltration served to evaluate on which day it was best to harvest leaves to 
achieve, qualitatively, the highest level of protein expression, and similarly at what bacterial 
concentration (OD600) expression was most effective. It also served to verify whether the P12A3C 
polypeptide expressed with pTRAc-P12A3C would in fact be cleaved into its component structural 
proteins (VP0, VP1, VP3) in plant host cells. Western Blot analysis of protein samples taken 3, 5, and 
7 days post infiltration, from plants infiltrated with infiltration medium  of OD600 0.5, revealed bands 
in line with the 25 kDa marker, which is aproximately the size of the FMDV VP1 and VP3 proteins 
which are of similar size, thus confirming cleavage of P12A (Figure 3.5). A second band in lane 2 was 
also observed between 32 KDa and 48 KDa markers appropriate for the size of VP0. A band in the 
region of the 80 KDa marker was also seen, which may possibly be uncleaved P12A. The VP3/VP1 
bands were most apparent in the samples harvested on day 3 and day 5; this is similar to expression 
of pRIC3.0-P1-2A3C and pEAQ-HT-P1-2A3C in plants – shown in previous work done in the BRU. 
Based on this observation, whole plant leaves were all harvested at 3 days post infiltration in 
subsequent large-scale plant expression experiments using vacuum infiltration. The optical density 











Figure 3.5. Western blot of gel comparing P12A-3C extracted from N.benthamiana leaf discs harvested 3, 5, and 7 days post 
infiltration lanes 2 – 4. Lane 1 = pTRAc-empty (negative control); lane 5 = Isolated FMDV positive control. Ladder used = NEB # 









similar band intensities (data not shown), with the exception of the observation that the highest 
optical density of approximately 0.75 resulted in more severe and more rapid leaf necrosis.   
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3.3.3 Comparison of scaled up protein expression using different vectors 
Having established that, like pRIC3.0-P12A3C and pEAQ-HT-P12A3c, expression of pTRAc-P12A3C 
also results in the FMDV VP0, VP1, and VP3 component proteins; infiltration using all three was 
scaled up for purification necessary for comparative purposes. 
 
3.3.4 Sucrose gradient purification protein analysis 
Protein purification involved a two-step ultracentrifugation procedure of the protein extract from 
the expression vectors pEAQ-HT-P12A3c, and pTRAc-P12A3C. The first ultracentrifugation step was 
carried out through a 30 % sucrose cushion to concentrate the FMDV proteins/VLPs in a pellet. 
Fractions from the supernatant, the 30% cushion region and the pellet separated on a SDS 
polyacrylamide gel showed the presence of VP0 and VP1/3 predominantly in the pellet for pTRAc-
P12A3C (figure 3.7) and pEAQ-HT-P12A3C (figure 3.9) suggesting that VLPs were present in these 
samples (comparison with pRIC3.0-P12A3C expression was only introduced later, with the 














Figure 3.6: Schematic representation of rate-zonal 
sucrose gradient 1 mL fractions in ultracentrifuge tube. 
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The re-suspended pellet was subsequently centrifuged through a rate-zonal sucrose gradient, 
initially 5 – 20 %, which was fractionated (40 fractions per construct). The position of each fraction 
relative to the rate-zonal gradient in the ultracentrifuge tube is illustrated schematically in figure 3.6.  
To minimise the number of fractions across which to sample for detection of the FMDV structural 
proteins by western blot, fractions were first dot-blotted (data not shown). The fractions displaying 
the darkest dots ranged from 1 to 10 for preparations from pTRAc-P12A3C and pEAQ-P12A3C vector 
constructs, and these were selected for analysis by SDS-PAGE and TEM. 
No obvious VP0 or VP1/3 bands were observed in the subsequent rate-zonal gradient fractions 
derived from the pTRAc-P12A3C construct (Figure 3.7 and 3.8), although a very faint band for VP0 
could be seen in fraction 2. By comparison, the band corresponding to VP3/VP1, as well as VP0 to a 
lesser extent, was clearly visible in the rate-zonal fractions 1, 2, 4, and 5, from the bottom of the 
tube (fraction 3 lost because of broken wells), expressed with the pEAQ-HT-P12A3C construct 
(Figure 3.9 and 3.10).  
The re-suspended pellet was then loaded onto a rate-zonal sucrose gradient, which was then 
fractionated. The position of each fraction relative to the rate-zonal gradient in the ultracentrifuge 
tube is illustrated schematically in figure 3.6. Each of these fractions, for each respective vector 
construct, was compared subject to a dot blot to indicate which fractions contained most of the 
expressed FMDV capsid proteins (data not shown). Fractions displaying the darkest dots, along with 
the respective neighbouring fractions that also showed significant reaction with anti-FMDV 
antibodies, were selected for analysis by SDS-PAGE and TEM viewing. Rate-zonal fraction samples 1 
– 10 were selected for comparison against each of the three fractions of the first centrifugation step 
through the 30 % sucrose cushion, by SDS-PAGE. Ten rate-zonal fractions were run against the crude 
supernatant, 30% cushion, and pellet, across two gels to accommodate all samples with controls and 
reference markers for both the pTRAc-P12A3C (Figure 3.7 and 3.8) and pEAQ-HT-P12A3C vector 









































Figure 3.7. Western blot of gel showing crude samples, and fractionated samples of protein extract form pTRAc-
P12A3C infiltrated plants, centrifuged through 5-20% rate zonal sucrose gradient. Lane 1 = supernatant, lane 2 
=30% sucrose cushion, lane 3 =pellet, lane 4 = fraction 1, lane 5= fraction 2, lane 6 = fraction 3, lane 7 = fraction 4, 


















Figure 3.8. Western blot of gel showing crude samples, and fractionated samples of protein extract form pTRAc-
P12A3C infiltrated plants, centrifuged through 5-20% rate zonal sucrose gradient. Lane 1 = fraction 5, lane 2 = 
fraction 6, lane 3 =, fraction 7, lane 4 =, fraction 8, lane 5 = fraction 9, lane 6 = fraction 10, lane 7 = fraction 4, Lane 
9 = Isolated FMDV positive control, lane 10 = pTRAc:empty (negative control). Ladder used = NEB # P7712S boad 




















Figure 3.10. Western blot of gel showing fractionated samples form protein extract of pEAQ-HT:P12A-3C 
infiltrated plants, centrifuged through 5-20 % rate zonal sucrose gradient. Lane 1 = fraction 5, lane 2 = fraction 6, 
lane 3 =, fraction 7, lane 4 =, fraction 8, lane 5= fraction 9, lane 6 = fraction 10, lane 7 = fraction 4, Lane 9 = 









Figure 3.9. Western blot (of gel2) showing crude and fractionated samples centrifuged through 5-20% rate zonal 
sucrose gradient form protein extract of pEAQ-HT:P12A-3C infiltrated plants. Lane 1 = supernatant from 30% 
sucrose cushion, lane 2 =30% sucrose cushion, lane 3 = pellet, lane 4 = fraction 1, lane 5= fraction 2, lane 6 -10= 

























FMDV proteins were enriched by pelleting them through the 30% sucrose cushion; Figures 3.7 and 
3.9 demonstrate the effective removal of most unwanted proteins during this purification step, 
evident when comparing the absence of non-specific bands and protein smear in the lane of the 
pellet, against the lanes of the 30% cushion and the supernatant which present cross reactivity with 
unwanted proteins – a protein smear throughout the lanes. Similarly, the effective removal of any 
residual unwanted proteins during purification through the sucrose gradient can also be observed 
when comparing the lane of fractions 1 and 2 displaying a distinct bands absent of any smear, 
against the lane of the pellet (Figure 3.9). Concentrations of the desired FMDV capsid proteins were 
perhaps slightly higher for pEAQ than for pTRAc, which may have been really low since the band for 
VP0 was really faint in fraction 2 and otherwise absent, while bands for VP0 and VP1/3 were 
comparatively easily discernible for pEAQ. 
Bands for both VP0 and VP1/3 are prominent in the pellet from the 30% cushion of pTRAc-P12A3C 
extract (Figure 3.7, lane 3), which was used for purification through the rate-zonal gradient, but 
these bands are absent in the subsequent rate-zonal fractions. This suggests the absence of any 
obvious VP1/3 bands in the rate-zonal fractions from pTRAc-P12A3C expressed protein (Figure 3.7 
and 3.8) was possibly a result of the FMDV particles pelleting at the base of the tube during the rate-
zonal ultracentrifugation step, instead of being suspended midway in the gradient. As the pellet was 
not collected this hypothesis could not be tested. To prevent the desired FMDV proteins or VLPs 
from pelleting during the rate-zonal gradient purification step, the rate-zonal centrifugation was 
repeated using a 15 – 40 % sucrose gradient with a reduced ultracentrifugation duration of 2 hours 
instead of 3 hours, adjusting the parameters to be more similar to those described by Cao et al. in 
their purification of FMDV capsid particles (Cao et al. 2009). Expression of FMDV capsid proteins 
with the vector construct pRIC3.0-P12A3C was introduced for comparison with pTRAc-P12A3C at this 
point. The gradient was fractionated and dot blots used to assess the predominant positions of the 
FMDV proteins as described above (data not shown). They were markedly different in that the 
predominance of the FMDV proteins in the gradient were shifted from fractions 1 to 10 to fractions 
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24 to 28.  For pRIC3.0-P12A3C, fraction 28 (two thirds up the gradient from the bottom of the tube) 
displayed the darkest spot, fraction 24 displayed the darkest spot for pTRAc-P12A3C and fraction 26 
displayed the darkest spot for pEAQ-HT P12A3C.  
Fractions 24 -28 for both pTRAc-P12A3C and pRIC3.0-P12A3C, purified through the 15 – 40 %, were 
selected then compared by western blot (Figure 3.12 and 3.13). Protein expressed with pEAQ, 
purified through 15 – 40 % sucrose gradient was not reanalysed by western blot as had already been 
done with 5 – 20 %, and was instead only compared by dot blot and then TEM (section 3.3.5). 
All five fractions (F24 to F28) from pTRAc-P12A3C, purified through a 15 – 40 % sucrose, displayed 
distinct bands of the sizes 25 kDa and 37 kDa appropriate for VP1/3 and VP0 respectively (Figure 
3.11). Only fractions 25, 27 and 28 of pRIC3.0-P12A3C expressed protein, purified through 15 – 40 % 

















- Ctrl  
pTRAc-P12A3C (15-40%) 
Figure 3.11. Western blot of gel comparing selected fractions of P12A3C expressed in N. benthamiana, using pTRAc 
purified with a 15% - 40% sucrose gradient (lanes 1-5), and pTRAc purified with a 5% - 20% sucrose gradient (Lane 
1 = pTRAc-P12A3C Fraction 24; lane 2 = pTRAc-P12A3C Fraction 25; lane 3 = pTRAc-P12A3C Fraction 26; lane 4 = 














Figure 3.12. Western blot of gel comparing selected fractions of P12A3C expressed in N. benthamiana, using pRIC3.0 purified 
with a 15% - 40% sucrose gradient (lanes 1-5), Lane 1 = pRIC3.0-P12A3C Fraction 24; lane 2 = pRIC3.0-P12A3C Fraction 25; lane 
3 = pRIC3.0-P12A3C Fraction 26; lane 4 = pRIC3.0-P12A3C Fraction 27; lane 5 = pRIC3.0-P12A3C Fraction 28; lane 10 = pRIC3.0-







3.3.5 Transmission electron microscopy 
Samples from the 15 to 40% gradients fractions described above were examined by TEM for the 
present of particles:  pTRAc-P12A3C - fraction 28, pRIC3.0-P12A3C - fraction 27 and pEAQ-HT-
P12A3C, fraction 28. In all cases, VLPs of 25 ± 5 nm in diameter were observed (Figures 3.13 - 3.15).  
These resembled FMDV and VLPs depicted in electron micrographs from literature (McKenna et al. 
1996; Li et al. 2012; Cao et al. 2009; Kotecha et al. 2015; Li et al. 2016; Liu et al. 2017; Xiao et al. 
2016; Veerapen et al. 2018). The VLPs uniformly appear as distinct, regular spherical/circular 
structures contrasting against the background debris, ranging slightly in size from 23 to 30 
nanometres in diameter (the length of the line drawn across the diameter is displayed in images 
3.13a, 3.14b, and 3.15a). Sizes of 23 – 30 nm are consistent with the size of FMDV virus particles and 
VLPs cited in literature (K. Strohaimer 1982; Grubman & Baxt 2004; Liu et al. 2017).  
Figure 3.13 displays sample derived from pEAQ-P12A3C with VLPs present; individual particle 
diameter lines were measured to be 27.77 and 28.59 nm. Figure 3.13 b displays a duplicate image of 
3.13a, with increased magnification. Figure 3.14 presents sample expressed with pRIC3.0-P12A3C, 
Figure 3.14b is a magnified image of the same sample, with particle diameters measuring 24.74, 
25.43, 26.94 nm. A sample of protein expressed with pTRAc-P12A3C is displayed in figure 3.15 with 
particle diameter measuring 23.71 nm, Figure 3.15b is a magnified image of the same sample. Figure 
3.16a and 3.16b display negative control samples of purified protein extract from plants infiltrated 
with pTRAc-empty and pEAQ-HT-empty respectively. No VLPs are present in these samples.  
These images provide supporting evidence that plant expressed FMDV viral capsid proteins were 
indeed able, with the presence of the 3C protease, to cleave appropriately into the respective 
individual structural proteins and self-assemble into VLPs. The sample derived from the plants 
infiltrated with pRIC3.0-P12A3C seemed to show many VLPs in the frame viewed (Figure 3.19a). 
However, it must be noted that TEM imaging was used solely for the qualitative assessment of 






Figure 3.16a: TEM image displaying absence of VLPs derived from a 
sample expressed by pTRAc-empty (negative control,) fraction 28. 
Reference scale bar = 100 nm.  
Figure 3.16b. TEM image displaying absence of VLPs derived from a 
sample expressed by pEAQ-empty (negative control), fraction 18. 
Reference scale bar = 100 nm 
Figure 3.15a. TEM image displaying VLPs (Identified by black arrows) 
derived from a sample expressed by pTRAc-P12A3C fraction 
28.Reference scale bar = 100 nm.  
Figure 3.15b. Magnified TEM image displaying VLPs (Identified by 
black arrows, with figures indicating the precise length of the line 
drawn across the diameter) derived from same sample expressed by 
pTRAc-P12A3C fraction 28.Reference scale bar = 50 nm 
a b 
Figure 3.13a: TEM image displaying VLPs (Identified by black arrows, 
with figures indicating the precise length of the line drawn across the 
diameter) derived from a sample expressed by pEAQ-P12A3C fraction 
28.Reference scale bar = 100 nm. 
Figure 3.13b: Magnified TEM image displaying VLPs (Identified by black 
arrows) derived from same sample expressed by pEAQ-P12A3C 
fraction 28.Reference scale bar = 50 nm. 
a b 
Figure 3.14a: TEM image displaying VLPs (Identified by black arrows) 
derived from a sample expressed by pRIC-P12A3C fraction 
27.Reference scale bar = 100 nm. 
Figure 3.14b: Magnified TEM image displaying VLPs (Identified by black 
arrows, with figures indicating the precise length of the line drawn 
across the diameter) derived from same sample expressed by .pRIC-




3.3.6 Protein yield quantification 
Quantification of expressed FMDV protein using all three expression vectors was done by 
densitometric analysis of Coomassie stained gels. Fractions were selected for each of the respective 
three constructs, and were independently quantified against a dilution series of Bovine serum 
albumin (BSA) ranging from 0.20 to 3.13 µg. 
Figures 3.19, 3.20 and 3.21 show the Coomassie-stained gels of proteins expressed using pTRAc-
P12A3C, pEAQ-HT-P12A3C and pRIC3.0-P21A3C, respectively, and Table 3.3 displays the estimated 
quantity of each. For pTRAc-P21A3C (Figure 3.19), fractions 24 and 25 showed distinct bands of 25 
kDa corresponding to VP1/3, while those of fractions 27 and 28 were comparatively faint; the 37 kDa 
band of VP0 was more visible in fractions 27 and 28 than in fractions 24 and 25. These bands 





















pTRAc - P12A3C  Standardised Bovine Serum Albumin 
Figure3.19. Coomassie stain comparing selected fractions of P12A3C expressed in N. benthamiana, using pTRAc- P12A3C (lanes 7-
10), purified with a 15% - 40% sucrose gradient. Lane 1 = Bovine Standard Albumin 3.13 µg; lane 2 = Bovine Standard Albumin 1.56 
µg; lane 3 = Bovine Standard Albumin 0.78 µg; lane 4 = Bovine Standard Albumin 0.39 µg; lane 5 = Bovine Standard Albumin 0.20 µg.  
lane 7 = pTRAc-P12A3C Fraction 24; lane 8 = pTRAc -P12A3C Fraction 25; lane 9 = pTRAc -P12A3C Fraction 27; lane 10 = pTRAc -
P12A3C Fraction 28; Ladder used = NEB # P7712S boad range protein marker.   
58 
 
For pEAQ-HT-P12A3C, no bands corresponding to the VP1/3 and VP0 proteins were detectable in 
any of the fractions tested (figure 3.20). 
 
For pRIC3.0-P12A3C, bands of 25 kDa were visible in fractions 23, 25, and 27 but not in 28. No VP0 
band of 37 kDa was visible in any fraction (figure 3.21).  
 
Quantification of FMDV protein was performed using densitometric SynGene™ software. pEAQ-HT-
























pRIC - P12A3C  Standardised Bovine Serum Albumin  
Figure 3.21. Coomassie stain comparing selected fractions of P12A3C expressed in N. benthamiana, using pRIC- P12A3C (lanes 7-
10), purified with a 15% - 40% sucrose gradient. Lane 1 = Bovine Albumin Standard 3.13 µg; lane 2 = Bovine Albumin Standard 1.56 
µg; lane 3 = Bovine Albumin Standard 0.78 µg; lane 4 = Bovine Albumin Standard 0.39 µg; lane 5 = Bovine Albumin Standard 0.20 
µg.  lane 7 = pRIC-P12A3C Fraction 24; lane 8 = pRIC -P12A3C Fraction 25; lane 9 = pRIC -P12A3C Fraction 27; lane 10 = pRIC -






















pEAQHT - P12A3C  Standardised Bovine Serum Albumin 
Figure3.20. Coomassie stain comparing selected fractions of P12A3C expressed in N. benthamiana, using pEAQ- P12A3C (lanes 7-
10), purified with a 15% - 40% sucrose gradient. Lane 1 = Bovine Standard Albumin 3.13 µg; lane 2 = Bovine Standard Albumin 1.56 
µg; lane 3 = Bovine Standard Albumin 0.78 µg; lane 4 = Bovine Standard Albumin 0.39 µg; lane 5 = Bovine Standard Albumin 0.20 µg.  
lane 7 = pEAQ -P12A3C Fraction 24; lane 8 = pEAQ -P12A3C Fraction 25; lane 9 = pEAQ -P12A3C Fraction 27; lane 10 = pEAQ -P12A3C 
Fraction 28; Ladder used = NEB # P7712S boad range protein marker. 
59 
 
kDa VP1/3 and 33 kDa VP0 bands visualised on Coomassie stained gels of pTRAc-P12A3C-expressed 
proteins, as well as the 25 kDa VP1/3 band visualised for pRIC3.0-P12A3C-expressed proteins were 
quantified. The respective bands selected for quantification are outlined with a black box (Figure 
3.19 and 3.21). The resulting data generated are presented in appendix C with accompanying 
calculations.  
Samples generated by the pTRAc-P12A3C vector, obtained from fractions 24, 25, 27 and 28 (Figure 
3.19), produced yield estimates of 1.25 µg/ g fresh leaf mass for the 25 kDa VP1/VP3 band (relevant 
calculations displayed in appendix C). Yield estimates for the 37 kDa VP0 band from the same 
fractions amounted to only 0.155 µg / g (appendix C). 
The estimated quantities for the band of VP1/3, generated by the pRIC3.0 vector (Figure 3.21), only 
amounted to 0.16 µg/ g of fresh leaf mass, (appendix C).  
 
Table 4 
Construct VP1/VP3  (µg/g fresh weight) VP0 (µg/g fresh weight 
pTRA 1.25 0.155 
pEAQ ND ND 
pRIC 0.16 ND 
ND Not determined 
These results suggest that the pTRAc-P12A3C vector was the best vector for generating higher yields 
of the desired FMDV capsid proteins.  
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3.4 Discussion and summary  
The full P12A gene for the FMDV structural proteins and 3C protease was successfully cloned into 
the pTRAc plant expression vector. FMDV structural proteins were successfully expressed in plant 
leaf tissue with each of the different recombinant vector constructs pTRAc, pEAQ, and pRIC3.0. 
Furthermore, electron microscopy provided images of virus-like particles (VLPs) resembling other 
TEM images of FMDV and VLPs presented in literature (McKenna et al. 1996; Kotecha et al. 2015), 
which confirmed that the expressed proteins were able to self-assemble into VLPs. 
Quantification was done by densitometry of a standardized dilution series instead of quantification 
by ELISA on account of not having a quantified control sample with a known concentration of FMDV 
proteins. A limitation of quantification using a Bradford assay, it could not distinguish plant 
expressed FMDV proteins from the other endogenous plant proteins still present after purification 
through the sucrose gradient, and would thus present an over estimate reflecting the total yield of 
all proteins present. Quantification by densitometry allowed the specific band of the appropriate 
size for the FMDV capsid proteins (VP1 and VP3, in the region of 25 kDa, being the most distinct) to 
be quantified relative to the bands of standardised BSA of a known concentration, thus providing a 
more accurate and specific yield estimate. The one limitation of the method is that it is dependent 
on effective Coomassie staining. 
Coomassie stain and densitometric comparison of protein expressed with each of the vectors used, 
suggested that the pTRAc-P12A3C vector is the most useful or effective vector for obtaining high 
yields of the recombinant P12A3C protein. No bands for the FMDV capsid proteins expressed with 
the pEAQ-HT vector were detectable with Coomassie staining for quantification despite positive 
detection with western blot. Antibodies used for protein detection by western blot are more 
sensitive and specific to the target protein and are thus capable of positive detection of the 
expressed protein even when the level of expression is insufficient to be evident with Coomassie 
stain. It should be further noted that the gel comparing the pEAQ-P12A3C derived samples (figure 
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20) was poorly stained; lanes 4 and 5 containing known amounts, 0.39 µg and 0.20 µg of the BSA 
control respectively, presented no visibly discernible bands and lane 3 containing 0.78 µg BSA was 
faint, compared with the staining of the gel comparing pTRAc-derived samples (figure 3.19) which 
presented clearly distinct bands in the lanes 4 and 5 of 0.39 µg and 0.20 µg BSA.  Although the 
amount of FMDV protein expressed using pEAQ-HT-P21A3C and staining was insufficient for 
densitometric quantification, expression with the pTRAc-P12A3C vector produced a yield of 75.5 µg 
of the antigenic structural proteins VP1 and VP3 from 60 g of fresh leaf material, equal to 1.25 µg /g, 
while densitometric estimates for the band of a size appropriate of VP0 amounted to a yield of only 
0.155 µg /g,(note though, that VP1 and VP3 have a combined yield; both proteins, being the same 
size, cannot be distinguished by Coomassie staining and quantified independently as VP0 is). 
Densitometric yield estimates for pRIC3.0-P12A3C amounted to only 0.16 µg /g. This amount is 
lower than might be expected considering pRIC vector was developed from pTRAc vector and 
modified for higher expression (Regnard et al. 2010). In theory pRIC, with the self-replicating vector 
construct producing gene replicons, should provide a higher level of expression and so deliver a 
greater yield. This yield estimate for pRIC3.0 also does not correlate well with the abundance of VLPs 
observed in TEM images, given that the expression was supposedly low one would expect to see 
relatively few VLPs. Despite pRIC having been developed from pTRAc for improved expression, a 
comparatively appreciable yield estimate was achieved with pTRAc. Since this quantification 
experiment was only performed once, on account of time constraints, repeated experiments to 
quantify the level of expression with these vectors would provide more definitive results and offer 
more credible yield estimates. It is possible that the poor yield could indicate a problem with the gel 
staining rather than poor expression. 
Both transient and transgenic expression of recombinant vaccine candidates in plants, have been 
investigated by various groups, as reviewed by Scotti and Rybicki. They reported a wide range in 
yield results (Scotti & Rybicki 2013); from as little as 32 mg/kg fresh leaf material with rotavirus VP7 
VP4, 0.18 g/kg with BPV1L1 , 0.24 g/kg with HPV-8, 0.3 g/kg with HBcAG, 0.34 g/kg with NVCP-VLP, 
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0.363 g/kg with HIV Pr55gag, to a high yield of 3 g/kg achieved with chloroplast targeted expression of 
HPV 16 L1, all transiently expressed in N. benthamiana, and 0.2 g/kg yield was obtained with 
transient expression of NVC-VLP in lettuce, while a variety of plant produced vaccine candidates by 
transgenic expression typically achieved significantly poorer yields as low as 4 ×10-6 g/kg for HPV-16 
L1 in tobacco, to 12 ×10-3 and 20 ×10-3 g/kg for human codon optimised HPV-16L1 in transgenic 
tobacco and potato respectively, too low to be viable for industrial production. More recently a 
chimeric protein  of the influenza M2e peptide transiently expressed in N. benthamiana produced 
high yields of approximately 1 g/kg fresh leaf tissue (Mardanova et al. 2015). The yields obtained 
with plant based expression systems, cited, offer promising prospects for the potential of this 
technology. However, the densitometric yield estimates of FMDV capsid proteins obtained with 
pTRAc-P12A3C expression in this study, are at the lower end of the range for protein yields from 
plant expression documented in literature. This suggests appropriate optimization of this 
methodology, may be capable of producing higher levels of the desired FMDV capsid proteins than 
what was achieved in this study. 
Even so, the yield obtained in this study may be sufficient for future industrial application. Standard 
chemically inactivated virus vaccine, currently in use, requires 2.2 µg of 146S particles of each 
respective FMDV serotype per dose in order to trigger effective protection in cattle (Daoud et al. 
2013). A yield of 75.5 µg of VP1/P3 obtained from 60 g fresh leaf mass with pTRAc exceed 2.2 µg 
required for protective immunization in cattle, and is easily obtained from as few as twenty N. 
benthamiana plants – approximately four to five weeks old. The term “large batch” in the context of 
this project would be an insignificant scale in an industrial context. Twenty of the small potted 
plants, approximately 30 cm in height (pot included), only occupy about 2000 cm2 of space 
(depending on spacing arrangement of the individual plants). Such small dimensions provide 
immense scope for upscaling to achieve protein yield necessary for commercial production. The 2.2 
µg/dose of viral antigen required for protection, according to Daoud et al. (2013), measures the 
mass of the full 146S particle; a complete FMDV virus particle inclusive of the 8.5 kb ssRNA. By 
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comparison, the yields measured in these experiments estimated the combined mass of VP1 and 
VP3. Theoretically the yield obtained for the entire empty viral capsids would thus be possibly higher 
still since VP0 (VP2 and VP4) did not contribute to these quantification estimates as it is not 
contained in the same band of the gel densitometrically assessed by the SynGene software. This 
yield should also theoretically equate to a greater copy number of VLPs per unit mass than the copy 
number of 146S virus particles per unit mass present in the inactivated vaccine. For any given mass 
of the antigenic FMDV, based on the simple premise: 
𝑣𝑖𝑟𝑎𝑙 𝑐𝑜𝑝𝑦 𝑛𝑢𝑚𝑏𝑒𝑟 =  
𝑚𝑒𝑎𝑠𝑢𝑟𝑒𝑑 𝑡𝑜𝑡𝑎𝑙 𝑚𝑎𝑠𝑠 𝑜𝑓 𝑎𝑙𝑙 𝑣𝑖𝑟𝑎𝑙 𝑐𝑜𝑚𝑝𝑜𝑛𝑒𝑛𝑡𝑠
𝑚𝑎𝑠𝑠 𝑜𝑓 𝑎 𝑠𝑖𝑛𝑔𝑙𝑒 𝑣𝑖𝑟𝑢𝑠 𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒
 
The mass of a single virus particle in the case of a 75S VLP is significantly less - it lacks the RNA that 
contributes to the mass of a full 146S particle (K. Strohaimer 1982), hence the denominator of the 
equation would be significantly reduced in the case of VLPs than it would be in the case of 146S 
infective virus particles, and would thus represent a yield with a far greater copy number of actual 
particles. The greater copy number should directly correlate to better exposure of the antigenic 
proteins necessary to induce an immunogenic response in vaccinated animals. The copy number 
theoretically is thus more relevant to the efficacy of a vaccine than the mass of the antigenic 
component. With this considered, these yield results provide particularly positive prospects for the 
potential of plant expression platforms, particularly in the context of recombinant FMDV VLPs as an 
alternative cost effective vaccine candidate. 
While this study used N. benthamiana for the production of FMDV structural proteins, other studies 
have produced FMDV derived proteins in different plants including alfalfa, (Dus Santos et al. 2005) 
and Arabidopsis (Carrillo et al. 1998). Exogenous FMDV polyepitope proteins have also been 
previously expressed in N. benthamiana (Andrianova et al. 2011). In this project FMDV capsid 
proteins were expressed and the self-assembling capacity of the FMDV structural polypeptide to 
form VLPs was also demonstrated. More specifically this study demonstrates that N. benthamiana 
presents a robust system for the expression of recombinant exogenous FMDV structural proteins 
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that retain the capacity to form VLPs, with appreciable yields. These works contribute to an 
accumulating body of research that demonstrates the scope and versatility of a plant based 
expression platform. In turn this provides further evidence supporting the potential of this 






Foot and mouth disease continues to be the most severe threat to the agricultural livestock industry 
worldwide. Outbreaks of this disease are among the most costly for government and farmers. 
Farmers invariably lose entire herds of livestock, while travel bans around quarantine areas, and 
trade restrictions, have a drastic impact on the economies of affected countries. The burden of this 
disease varies among countries as many regions have been free of the disease for many years. In 
South Africa, however, foot and mouth disease virus is endemic to the region and exists naturally in 
the buffalo population, an asymptomatic host of the virus, which thus acts as a natural reservoir of 
the virus (Thomson 1995). Constant monitoring and control is consequently an absolute necessity in 
the South African context in order to mitigate the spread, and burden of the disease. A vaccine is 
recognised as the most effective long-term solution to prevent the spread of the disease into herds 
of livestock. 
The work in this study has demonstrated that N. benthamiana can be used as a plant expression 
platform for the development of virus-like particles (VLPs) that could serve as an effective 
alternative candidate vaccine to the traditional chemically inactivated FMDV virus vaccine currently 
in use, which carries both a high biosafety risk and high production cost. Specifically in this project, 
the FMDV VP1, 3, and 0 structural capsid proteins derived from the P12A gene of serotype A were 
expressed in combination with the 3C protease in N. benthamiana via an agrobacterium - mediated 
transient expression system.  
Antibodies for these structural proteins are not readily available locally. To address this problem the 
P12A oligopeptide was expressed in an E. coli expression system for the rapid production of the 
protein. The 3C protease was excluded from the gene expressed in E. coli as the 3C protease is not 
conducive to E. coli growth. E. coli expressed P12A product was used to raise antibodies against the 
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protein in rabbits. These antibodies could then be used for the detection of the FMDV structural 
proteins expressed in plants by analysis with western blot.  
Expression of the viral proteins in the plants could be observed three days after infiltration of the 
plant leaves. Furthermore, expression of the viral proteins was observed with the use of each of the 
three vectors used for the gene expression: pTRAc, pRIC3.0, pEAQ-HT. Densitometry estimates of 
75.5 µg VP1 and VP3 protein, expressed using pTRAc-P12A3C vector, was obtained from 60 g leaf 
material. Virus protein yield of 1.25 mg/kg fresh leaf weight, with pTRAc-P12A3C, was higher than 
yields obtained with the use of the pRIC3.0-P12A3C and pEAQ-HT-P12A3C vectors. Only 2.2 µg/dose 
of the 146S infective FMDV virus is necessary to induce protection in cattle. Thus a protein yield of 
1.25 mg/kg may be sufficient to justify testing the viability of this plant expression methodology for 
the industrial production of FMDV VLPs as a candidate vaccine. The auto assembly of the viral 
proteins into virus-like particles was also observed with each of the three vectors, as confirmed with 
transmission electron microscopy imaging. 
Although beyond the scope of this particular project, what remains to be done in order for this 
research to ultimately contribute towards the establishment of a viable vaccine is to conduct animal 
trials to investigate the efficacy of the plant produced VLPs and the protection elicited in animals 
tests. 
Animals vaccinated with this VLP vaccine would be distinguishable from infected animals by 
standard ELISA testing for FMDV non-structural proteins absent from the VLPs. This would be 
significant for the monitoring of livestock surrounding the Kruger National Park and other foot-and-
mouth disease zones, as it is currently not possible to distinguish between the vaccinated and 
infected animals, since in both instances both the structural and non-structural proteins of complete 
146S FMDV present. This is one of the most critically beneficial aspects of a VLP vaccine. This could 
also potentially have international trade legislation reconsidered and the classification of FMDV-free 
zones amended.  
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VLPs present structural mimics of the original parent virus to the immune system, incorporating all 
of the structural proteins. The use of VLPs as vaccines thus offer potentially better protection than 
using sub-unit vaccines, as the immune system is exposed to all of the structural proteins rather than 
a single protein or select protein motifs and epitopes. While being structural mimics of the parent 
virus, they do not contain any of the genomic material nor any of the non-structural proteins and 
hence are non-virulent, making them safer and far more appealing candidates for vaccine use than 
inactivated live virus particles. The ability to produce VLPs efficiently presents exciting prospects for 
the future of vaccine technology. 
The advantages and disadvantages of the various expression systems currently available have been 
described and the preference towards such a plant based expression system has been highlighted. 
Of particular relevance to the candidate vaccine’s potential as a commercial product, is the 
economic viability presented by the plant expression system, as is the scope for ease of upscaling 
necessary for industrialization of the production process, with minimal demands on upgrading 
infrastructure. This advantage is particularly important in sub-Saharan Africa where many countries 
are underdeveloped - the facilities and infrastructure necessary for large scale protein production via 
various alternative cell culture expression platforms, do not exist and would require huge capital 
expenditure. Growing plants, by comparison, can be achieved across a wider range of environments 
and does not require any significant infrastructure. This is possibly the most compelling advantage of 
this expression platform in the African context as it makes the technology far more accessible to 
under developed nations and more rural regions.  
The prospects of this technology continue to improve with further research in the field as 
optimisation and discoveries reduce cost, improve efficiency, increase yield, and widen the scope of 
application; presenting an exciting and promising future. 
The potential of this plant expression system has been effectively demonstrated by the successful 
production of recombinant FMDV structural protein using N. benthamiana in this study. The 
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subsequent assembly of VLPs derived from the plant expression platform was also demonstrated. 
These VLPs could be used as a safer candidate vaccine against FMDV in the future. 
The adopted approach and technology used to develop this potential vaccine is applicable globally 
and would be particularly beneficial to South Africa and other developing nations. Foot and mouth 
disease for which the vaccine was developed, is also prevalent across the globe but is particularly 
relevant to the South African context. 
In essence this work has demonstrated the feasibility of producing a vaccine candidate that would 
be more affordable, especially for farmers of developing countries here in Africa. The 
implementation of its production would be both more feasible and more economical than vaccine 
production currently is for local companies or government. This technology and it’s product,  the 
potential candidate vaccine, has the potential to significantly alleviate the impact caused by the 
devastating disease, especially in South Africa and those countries constantly affected by FMD. The 
vaccine could alleviate both economic cost incurred as a result of FMD, and also the conservational 
hindrance of free movement of people and all animal species, through FMD infectious areas. Both 
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Appendix A: P12A3C Nicotiana optimised DNA sequence  
by GenScript 
 
                                 -10       0         10        20        30        40        50        60        70        80                            
                                .|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|... 
Sec sin optimizar               ~~~~~~~~~~~~GGGGCTGGACAATCCAGCCCAGCTACTGGCTCGCAGAACCAATCTGGTAACACAGGTAGCATAATCAACAACTACTACATGCAACAGT  
optimized sequence by Genscrip  ~~~~~~~~~~~~GGAGCAGGTCAATCAAGTCCAGCAACAGGTTCACAGAATCAATCAGGAAATACAGGATCTATCATCAACAACTACTACATGCAACAGT  
 
                                 90       100       110       120       130       140       150       160       170       180                   
                                .|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|... 
Sec sin optimizar               ACCAAAACTCCATGGACACACAGCTTGGTGACAATGCCATCAGTGGAGGCTCTAACGAGGGCTCCACGGACACAACTTCAACTCACACAACCAACACCCA  
optimized sequence by Genscrip  ATCAAAATTCTATGGATACTCAGCTTGGAGATAATGCTATTAGTGGTGGATCTAACGAAGGTTCAACTGATACTACAAGTACACATACCACTAATACCCA  
 
                                 190      200       210       220       230       240       250       260       270       280                   
                                .|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|... 
Sec sin optimizar               AAACAATGACTGGTTTTCAAGACTCGCCAGTTCGGCCTTCTCCGGTTTGTTTGGGGCCTTGCTTGCCGACAAGAAGACGGAGGAGACGACACTCCTTGAG  
optimized sequence by Genscrip  AAATAACGATTGGTTTTCAAGATTAGCTTCTTCAGCTTTTTCTGGTCTCTTCGGAGCTCTTTTGGCAGATAAGAAAACTGAAGAGACAACCTTACTCGAA  
 
                                 290      300       310       320       330       340       350       360       370       380                   
                                .|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|... 
Sec sin optimizar               GACCGCATTCTCACCACTCGTAATGGGCACACCACCTCCACGACCCAGTCCAGCGTAGGCGTTACATACGGGTACTCCACAACAGAGGACCACGTTGCTG  
optimized sequence by Genscrip  GATAGAATTCTTACTACAAGGAATGGTCATACCACTTCTACAACCCAAAGTTCTGTTGGTGTGACATATGGATACTCAACTACAGAGGATCACGTTGCTG  
 
                                 390      400       410       420       430       440       450       460       470       480                   
                                .|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|... 
Sec sin optimizar               GACCCAACACATCAGGTTTGGAGACACGAGTGGTACAGGCAGAGAGATTCTACAAAAAGTTTTTGTTTGATTGGACAACGGACAAGCCTTTTGGACACCT  
optimized sequence by Genscrip  GTCCTAATACTAGTGGATTGGAAACAAGAGTTGTGCAGGCAGAGAGGTTCTATAAGAAGTTCTTGTTCGATTGGACCACTGATAAGCCTTTCGGTCATCT  
 
                                 490      500       510       520       530       540       550       560       570       580                   
                                .|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|... 
Sec sin optimizar               GCACAAACTGGAGTTGCCCACCGACCACTACGGTGTTTTCGGACACTTGGTGGACTCATACGCCTACATGAGGAACGGTTGGGACGTTGAGGTGTCTGCT  
optimized sequence by Genscrip  TCACAAACTTGAATTGCCAACAGATCATTACGGTGTTTTTGGACACCTTGTGGATAGTTATGCTTACATGAGGAATGGTTGGGATGTTGAGGTGTCTGCA  
 
                                 590      600       610       620       630       640       650       660       670       680                   
                                .|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|... 
Sec sin optimizar               GTTGGCAACCAGTTCAACGGCGGATGCCTCCTAGTGGCCATGGTACCCGAATGGAAAGAGTTTGAAACGCGGGAGAAGTACCAGCTCACGCTTTTCCCGC  
optimized sequence by Genscrip  GTTGGAAATCAGTTTAACGGTGGATGTCTTTTGGTTGCTATGGTGCCTGAGTGGAAGGAATTCGAGACAAGAGAGAAGTACCAACTCACCCTCTTTCCTC  
 
                                 690      700       710       720       730       740       750       760       770       780                   




Sec sin optimizar               ACCAGTTCATTAGCCCCAGAACCAACATGACTGCCCACATCACGGTTCCTTACCTTGGTGTGAATAGATATGATCAGTACAGAAAACACAAACCCTGGAC  
optimized sequence by Genscrip  ATCAGTTCATTTCTCCAAGGACTAATATGACAGCTCACATCACTGTTCCATACTTGGGAGTGAACAGATATGATCAATACAGGAAGCATAAACCTTGGAC  
 
                                 790      800       810       820       830       840       850       860       870       880                   
                                .|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|... 
Sec sin optimizar               ACTGGTTGTCATGGTCGTGTCCCCGCTCACGGCCAACGCCACGAGCGCGGCACAGATCAAGGTCTATGCCAACATCGCTCCGACCTACGTTCATGTGGCC  
optimized sequence by Genscrip  ACTTGTTGTGATGGTTGTGTCTCCATTGACAGCTAATGCAACCTCAGCTGCACAGATTAAAGTTTATGCTAACATCGCACCTACTTACGTTCATGTGGCT  
 
                                 890      900       910       920       930       940       950       960       970       980                   
                                .|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|... 
Sec sin optimizar               GGCGAGCTCCCCTCGAAAGAGGGGATCTTCCCTGTCGCGTGCGCGGACGGTTACGGAGGACTGGTGACAACGGACCCGAAAACAGCTGACCCCGCCTACG  
optimized sequence by Genscrip  GGTGAACTTCCTTCAAAGGAGGGAATTTTTCCAGTGGCTTGCGCAGATGGTTATGGTGGATTGGTTACAACCGATCCTAAGACAGCTGATCCAGCATATG  
 
                                 990      1000      1010      1020      1030      1040      1050      1060      1070      1080                  
                                .|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|... 
Sec sin optimizar               GCAAGGTGTACAATCCGCCCCGGACTAACTACCCCGGGCGTTTCACCAACTTGTTGGACGTGGCTGAGGCATGTCCCACCTTTCTGTGTTTTGACGACGG  
optimized sequence by Genscrip  GAAAAGTTTACAATCCTCCAAGAACTAACTACCCAGGAAGGTTTACAAATCTTCTCGATGTTGCTGAAGCATGTCCTACTTTTCTTTGCTTCGATGATGG  
 
                                 1090     1100      1110      1120      1130      1140      1150      1160      1170      1180                  
                                .|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|... 
Sec sin optimizar               GAAACCGTACGTTACCACACAGACAGGTGAGTCTCGTCTTCTGGCCAAGTTCGACCTTTCCCTTGCCGCGAAGCACATGTCTAACACATATTTGGCAGGA  
optimized sequence by Genscrip  AAAGCCATATGTTACTACACAAACAGGAGAGTCTAGACTTTTGGCTAAGTTCGATCTTAGTTTGGCTGCAAAACATATGTCTAATACTTATCTTGCTGGT  
 
                                 1190     1200      1210      1220      1230      1240      1250      1260      1270      1280                  
                                .|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|... 
Sec sin optimizar               ATTGCCCAGTACTACACACAGTACTCGGGCACCATCAATTTGCATTTCATGTTCACAGGTTCAACTGATTCAAAAGCCCGCTACATGGTGGCTTACATCC  
optimized sequence by Genscrip  ATTGCACAATATTACACCCAGTACTCAGGAACTATCAACTTGCACTTTATGTTCACTGGTTCAACTGATAGTAAGGCTAGATATATGGTTGCATACATTC  
 
                                 1290     1300      1310      1320      1330      1340      1350      1360      1370      1380                  
                                .|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|... 
Sec sin optimizar               CGCCTGGGGTGGAAACACCACCGGATACACCTGAGAGGGCAGCCCACTGCATCCATGCTGAGTGGGACACAGGGTTGAATTCCAAATTCACATTCTCAAT  
optimized sequence by Genscrip  CTCCAGGAGTGGAAACTCCTCCAGATACACCTGAGAGGGCTGCACATTGTATTCACGCTGAATGGGATACTGGTCTTAACTCTAAGTTTACTTTCTCAAT  
 
                                 1390     1400      1410      1420      1430      1440      1450      1460      1470      1480                  
                                .|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|... 
Sec sin optimizar               CCCGTACGTGTCTGCCGCGGATTACGCCTACACGGCGTCTGATGAGGCAGAGACAACAAACGTACAGGGATGGGTCTGCGTTTACCAGATCACACACGGG  
optimized sequence by Genscrip  CCCATACGTTAGTGCTGCAGATTATGCTTACACTGCAAGTGATGAAGCTGAGACCACTAATGTTCAAGGATGGGTTTGCGTGTATCAGATTACTCATGGT  
 
                                 1490     1500      1510      1520      1530      1540      1550      1560      1570      1580                  
                                .|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|... 
Sec sin optimizar               AAGGCTGACAACGACACTCTGGTCGTATCGGTTAGCGCCGGCAAGGACTTCGAGTTGCGCCTCCCCATTGACCCCCGACCGCAGACCACCGCTACTGGGG  
optimized sequence by Genscrip  AAAGCTGATAACGATACATTGGTTGTGTCAGTTAGTGCAGGAAAGGATTTTGAATTAAGACTCCCTATCGATCCTAGGCCACAGACAACCGCTACAGGTG  
 
                                 1590     1600      1610      1620      1630      1640      1650      1660      1670      1680                  
                                .|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|... 
Sec sin optimizar               AATCAGCAGACCCTGTCACCACCACTGTAGAGAACTACGGCGGTGAGACACAAGTTCAGAGACGCCACCACACCGACGTTGGCTTCATCATGGACAGATT  
optimized sequence by Genscrip  AATCTGCAGATCCAGTTACTACAACCGTGGAAAATTATGGTGGAGAGACCCAAGTTCAGAGAAGGCATCACACTGATGTGGGTTTTATTATGGATAGATT  
 





                                .|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|... 
Sec sin optimizar               TGTGAAAATAAACAGCCCAAAATCCACCCATGTCATTGACCTCATGCAAACCCACCAACACGGTCTAGTGGGTGCGCTGCTGCGTGCGGCGACCTACTAC  
optimized sequence by Genscrip  CGTTAAGATCAACTCTCCTAAATCAACACATGTGATTGATCTTATGCAAACCCATCAGCACGGTCTCGTTGGAGCTTTACTCAGAGCTGCAACTTACTAC  
 
                                 1790     1800      1810      1820      1830      1840      1850      1860      1870      1880                  
                                .|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|... 
Sec sin optimizar               TTCTCAGATCTGGAAATTGTTGTGCGGCACGACGGTAACCTAACTTGGGTGCCCAATGGTGCTCCCGTGTCAGCCTTGTCCAACACCAGCAACCCCACCG  
optimized sequence by Genscrip  TTCTCTGATCTTGAAATCGTTGTGAGGCACGATGGTAATCTCACATGGGTTCCTAACGGAGCTCCAGTGAGTGCACTTTCTAATACCTCAAACCCTACTG  
 
                                 1890     1900      1910      1920      1930      1940      1950      1960      1970      1980                  
                                .|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|... 
Sec sin optimizar               CCTACAACAAGGCACCGTTCACGAGACTTGCCCTCCCCTACACCGCGCCACACCGCGTGTTGGCGACTGTGTACAACGGGACGAGCAAGTACACTGTGAG  
optimized sequence by Genscrip  CTTATAATAAGGCACCATTCACAAGACTTGCTTTGCCTTACACCGCACCACATAGGGTTCTTGCTACTGTGTATAACGGTACATCAAAGTACACCGTTAG  
 
                                 1990     2000      2010      2020      2030      2040      2050      2060      2070      2080                  
                                .|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|... 
Sec sin optimizar               TGGGTTAAGCAGACGAGGCGACTTGGGTTCCCTCGCGGCACGAGTCGCGAAGGCACTTCCTGCTTCTTTCAACTACGGTGCAATCAAGGCCGTCAACGTG  
optimized sequence by Genscrip  TGGATTGTCTAGAAGGGGAGATCTTGGATCTTTGGCTGCAAGGGTTGCTAAGGCATTGCCAGCTTCTTTTAATTACGGAGCTATTAAAGCAGTTAACGTG  
 
                                 2090     2100      2110      2120      2130      2140      2150      2160      2170      2180                  
                                .|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|... 
Sec sin optimizar               CACGAGCTTCTCGTGCGCATGAAACGGGCCGAACTCTACTGCCCTAGACCACTGTTGGCACTAGAGGTGATCTCACAAGACAGACACAAACAGAAGATCA  
optimized sequence by Genscrip  CATGAACTTCTTGTTAGGATGAAGAGGGCTGAGCTTTACTGTCCTAGACCATTACTCGCATTGGAAGTTATTTCTCAAGATAGGCACAAGCAGAAAATTA  
 
                                 2190     2200      2210      2220      2230      2240      2250      2260      2270      2280                  
                                .|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|... 
Sec sin optimizar               TTGCACCCGAAAAACAGCTTTTGAACTTCGACCTGCTCAAGTTGGCGGGAGACGTTGAGTCCAACCCTGGGTTCGAAAGTGGTGCCCCACCGACCGACCT  
optimized sequence by Genscrip  TCGCTCCTGAGAAGCAACTTTTGAACTTCGATCTTCTCAAACTTGCTGGAGATGTTGAATCTAACCCAGGTTTCGAGTCAGGAGCACCTCCAACTGATTT  
 
                                 2290     2300      2310      2320      2330      2340      2350      2360      2370      2380                  
                                .|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|... 
Sec sin optimizar               GCAGAAGATGGTCATGGGCAACACAAAGCCTGTTGAGCTTATTCTCGACGGGAAGACAGTAGCCATCTGCTGCGCTACTGGAGTGTTCGGCACTGCCTAC  
optimized sequence by Genscrip  GCAGAAGATGGTTATGGGAAATACAAAACCTGTGGAATTAATTCTCGATGGAAAGACTGTTGCTATCTGTTGCGCAACAGGTGTTTTTGGAACCGCTTAT  
 
                                 2390     2400      2410      2420      2430      2440      2450      2460      2470      2480                  
                                .|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|... 
Sec sin optimizar               CTCGTGCCTCGTCATCTTTTCGCTGAGAAGTACGACAAGATCATGCTGGACGGCAGAGCCCTGACAGACAGTGACTACAGAGTGTTTGAGTTTGAGATTA  
optimized sequence by Genscrip  CTTGTGCCAAGACATTTGTTCGCAGAGAAGTACGATAAAATTATGCTCGATGGAAGAGCTCTCACAGATTCAGATTATAGGGTTTTTGAATTCGAGATCA  
 
                                 2490     2500      2510      2520      2530      2540      2550      2560      2570      2580                  
                                .|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|... 
Sec sin optimizar               AAGTAAAAGGACAGGACATGCTCTCAGACGCTGCGCTCATGGTGCTTCACCGTGGGAACCGCGTGAGAGACATCACGAAACACTTTCGTGACACAGCTAG  
optimized sequence by Genscrip  AGGTGAAAGGACAAGATATGCTTAGTGATGCTGCATTAATGGTTCTCCATAGAGGTAATAGAGTGAGGGATATTACCAAGCACTTTAGAGATACTGCTAG  
 
                                 2590     2600      2610      2620      2630      2640      2650      2660      2670      2680                  
                                .|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|... 
Sec sin optimizar               AATGAAGAAAGGCACCCCCGTTGTTGGCGTTATCAACAACGCTGACGTCGGGAGACTGATCTTCTCTGGTGAAGCCCTTACCTACAAGGACATTGTAGTG  





                                 2690     2700      2710      2720      2730      2740      2750      2760      2770      2780                  
                                .|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|... 
Sec sin optimizar               TGCATGGACGGAGACACCATGCCAGGGCTTTTTGCCTACAAAGCCGCAACTAAGGCTGGCTATTGCGGAGGGGCCGTTCTCGCAAAGGACGGAGCCGACA  
optimized sequence by Genscrip  TGTATGGATGGAGATACTATGCCAGGACTTTTCGCTTATAAGGCTGCAACAAAAGCAGGTTACTGCGGTGGAGCTGTGTTGGCAAAGGATGGTGCTGATA  
 
                                 2790     2800      2810      2820      2830      2840      2850      2860      2870      2880                  
                                .|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|... 
Sec sin optimizar               CTTTCATCGTTGGCACCCACTCTGCTGGAGGCAATGGAGTTGGTTACTGCTCATGCGTTTCCAGGTCCATGCTCCAAAAGATGAAGGCACACGTCGACCC  
optimized sequence by Genscrip  CTTTCATTGTTGGAACACATAGTGCAGGTGGAAATGGTGTTGGATATTGTTCTTGCGTGTCTAGATCAATGTTGCAGAAGATGAAAGCTCACGTTGATCC  
 
                                 2890     2900      2910      2920      2930      2940      2950   
                                .|....|....|....|....|....|....|....|....|....|....|....|....|.. 
Sec sin optimizar               GGAGCCACACCACGAAGGGTTGATTGTTGACACCAGAGATGTGGAAGAACGCGTTCACGTGATG  




Appendix B: Composition of Buffers and Solutions 
 
GROWTH MEDIA: (1 L ) 
LB-Lennox:  
10 g tryptone  
5 g yeast extract  
5 g NaCl  
15 g of agar added* 
Volume brought to ≤900 mL with distilled water water 
pH adjusted to 7  
Volume brought to 1 L with distilled water water  
Autoclaved 
*Used only when making LB-agar plates 
  
Infiltration Medium: (1 L) 
1.952 g MES 
2.03 g MgCl2 (4.34g hydrated) 
30 g Sucrose 
Make up to 800mL with distilled water  
pH adjusted to 5.6 with HCl 
Add distilled water to 1 L 
1 mL 0.2 M acetosyringone (final conc 200 uM) added just before use 
 
BUFFERS FOR SDS-PAGE and coomasie stain: 
1.5 M Tris, pH 8.8; Resolving Buffer for separating gels (200 mL for 4 gels)  
36.3 g Tris base dissolved in 180 mL of distilled water  
pH adjust to 8.8 with concentrated HCl  
volume raised to 200mL with distilled water  
 
1.5 M Tris, pH 6.8; Stacking Buffer for stacking gels (50 mL for 4 gels) 
3g Tris base dissolved in around 40 mL of distilled water  
pH adjusted to 6.8 with concentrated HCl  
volume raised to 50mL with distilled water  
 
10x Electrophoresis running buffer (1L) 
30.3g Tris base  
144.2g glycine  
10g SDS  
Dissolved with heat and pH adjusted to 8.5 with HCl 
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Volume raised to 1L with distilled water  
 
1% Coomassie Blue stock solution: (100 mL ) 
Dissolve 1 g Coomassie Brilliant Blue G-250 in 100mL dH20 
 
Coomassie Blue Stain: (500 mL ) 
62.5 mL 1% Coomassie Blue Stock solution 
250 mL Methanol 
80 mL Glacial Acetic Acid 
127 mL distilled water 
 
Stain/destain solution: (1L)  
450 mL Methanol 
450 mL distilled water 
100 mL Glacial Acetic acid 
 
5x sample loading buffer: (5mL ) 
470 µL 1M TrisCl pH7.5 
940 µL 10% SDS 
19 µL 0.5M EDTA 
2.45 mL glycerol  
545 µL ddistilled water 
205 µL Mercaptoethanol 




BUFFERS FOR WESTERN BLOTTING: 
 
10x Phosphate Buffered Saline (PBS): (1L) 
17.8 g Na2HPO4.2H2O  
2.4 g KH2PO4, 
80 g NaCl , 
2 g KCl,  
Dissolved in 800 mL distilled water 
pH adjusted to 7.4 with 10 M NaOH 





1x Transfer buffer: (1 L)  
5.82 g Tris base 
2.93 g Glycine 
200 mL methanol  
cold distilled water to 1 L 
pH 9.2 
 
10% Tween-20: (100 mL ) 
10 mL Tween-20 added to 90 mL distilled water  
Filter sterilized 
Stored in the dark 
 
Blocking Buffer: (100 mL ) 
5 g Milk Powder dissolved in around 70 mL distilled water 
10 mL 10x PBS and 1 mL 10% Tween 20 added 
distilled water added to 100 mL  
 
GENERAL USE BUFFERS: 
 
1% Bovine Serum Albumin: (10 mL ) 
100 mg BSA (Pentax Fraction v) dissolved in 10mL ddH20, Filter sterilized, stored at – 20  
 
6x DNA loading buffer: (10 mL)  
4 g sucrose and 24.04 g bromophenol blue dissolved in 8mL distilled water 
400 µL 0.5 M EDTA added 
Volume brought to 10 mL with distilled water, Filter sterilized  
 
1% Agarose: (100mL ), 
1 g Agarose added to 100 mL 1 X TBE buffer 
2.5 µL 10 mg/mL EtBr added per 50 mL agarose after melting 
 
Buffer QBT (equilibration buffer):  
750 mM NaCl 
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50 mM MOPS pH 7.0 
15 % Isopropanol (v/v) 
0.15% Triton X-100 (v/v) 
 
Buffer QC: 
1.0 M NaCl 
50 mM MOPS pH 7.0 
15 % (v/v) isopropanol 
 
Buffer QF: 
1.25 M NaCl 
50m M Tris.Cl pH 8.5 
15% (v/v) isopropanol 
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Appendix C: FMDV capsid protein quantification 
 
SynGene™ software yield calculations for protein produced via pTRAC-P12A3C. 
 
Bovine Serum Albumin quantity calibration details  































Curve type Linear through origin (mutliple standard values) 
Calibrate All tracks to a single curve. Units µg 
 
Calibrated quantity - ug 
 
Raw volume   (  Y =  0  +1.03e-005  * x    ; R = 0.967 ) 
 
  










 Profile height 
Figure A5: Track 5; BSA = 0.20 µg, Profile height = 20.758 
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VP1/3 produced by pTRAc-P12A3C; 15 – 40 % sucrose gradient purification 
gels loaded with 30 µL sample + 6 µL SAB 
 
lane 7, fraction 24, densitometry quantity estimate of VP1/VP3 25 kDa band = 1.23 µg  
1.23 µg × (1mL /0.03mL)  












lane 8, fraction 25, densitometry quantity estimate of VP1/VP3 25 kDa band = 0.86 µg 
0.86 µg × (1mL /0.03mL)  












lane 9, fraction 27, densitometry quantity estimate of VP1/VP3 25 kDa band = 0.11 µg 
0.11 µg × (1mL /0.03mL)  











lane 10, fraction 28, densitometry quantity estimate of VP1/VP3 25 kDa band = 0.07 µg 
0.07 µg × (1mL /0.03mL)  
= 2.3 µg of desired FMDV VP1/VP3 capsid protein in total 1 mL fraction 28 
 
Total yield ≈ ∑ fractions 24, 25, 27, 28 
41 µg + 28.6 µg + 3.6 µg + 2.3 µg 
= 75.5 µg yield from 60 g fresh leaf mass 






Figure A9: Track 8; VP1/3 = 0.07 µg, Profile height = 4.579 
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mystery band produced by pTRAc-P12A3C; 15 – 40 % sucrose gradient purification 
gels loaded with 30 µL sample + 6 µL SAB 
 
 
lane 7, track 6, fraction 24, densitometry quantity estimate of mystery <32 kDa band = 1.87 µg  
1.87 µg × (1mL /0.03mL)  
= 62.3 µg of desired FMDV mystery protein in total 1 mL fraction 24 
  
1 








lane 8, track 7, fraction 25, densitometry quantity estimate of mystery <32 kDa band = 1.71 µg 
1.71 µg × (1mL /0.03mL)  
= 57 µg of desired FMDV mystery protein in total 1 mL fraction 25 
  
1 









lane 9, track 8, fraction 27, densitometry quantity estimate of mystery <32 kDa band = 0.89 µg 
0.89 µg × (1mL /0.03mL)  
= 29.6 µg of desired FMDV mystery protein in total 1 mL fraction 27 
  
1 









lane 10, track 9,  fraction 28, densitometry quantity estimate of mystery <32 kDa band = 0.42 µg 
0.42 µg × (1mL /0.03mL)  
= 14 µg of desired FMDV mystery protein in total 1 mL fraction 28 
 
Total yield ≈ ∑ fractions 24, 25, 27, 28 
62.3 µg + 57 µg + 29.6 µg + 14 µg 
= 162.9 µg yield from 60 g fresh leaf mass 
= 2.715 × 10-6 or 0.0002715 %  
1 




Figure A15: Track 9; mystery = 0.42 µg, Profile height = 23.621  
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VP0 produced by pTRAc-P12A3C; 15 – 40 % sucrose gradient purification 
gels loaded with 30 µL sample + 6 µL SAB 
 
lane 9, track 6, fraction 27, densitometry quantity estimate of VP0 37 kDa band = 0.18 µg 
0.18 µg × (1mL /0.03mL)  












lane 10, track 7, fraction 28, densitometry quantity estimate of VP0 37 kDa band = 0.10 µg 
0.10 µg × (1mL /0.03mL)  
= 3.3 µg of desired FMDV VP0 capsid protein in total 1 mL fraction 28 
 
Total yield ≈ ∑ fractions 27, 28 
6 µg + 3.3 µg  
= 9.3 µg yield from 60 g fresh leaf mass = 0.155 µg/g 
= 1.55 × 10-7 or 0.0000155 %   
1 




Figure A17: Track 7; mystery = 0.10 µg, Profile height = 8.434 
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SynGene™ software yield calculations for protein produced via pRIC3.0--P12A3C  
Bovine Serum Albumin quantity calibration details 






Figure A21: Track 2; BSA = 1.56 µg, Profile height = 68.035 





Curve type Linear through origin (mutliple standard values) 
Calibrate All tracks to a single curve. Units µg 
 
Calibrated quantity - ug 
Raw volume   (  Y =  0  +8.63e-006  * x    ; R = 0.998 ) 






Figure A22: Track 3; BSA = 0.78 µg, Profile height = 45.086 
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 gels loaded with 30 µL sample + 6 µL SAB 
  
lane 6, track 6, fraction 24, densitometry quantity estimate of VP1/VP3 25 kDa band = 2.28 µg 
2.28 µg × (1mL /0.03mL)   
= 7.6 µg of desired FMDV VP1/VP3 capsid protein in total 1 mL fraction 24 
  




lane 7, track 7, fraction 25, densitometry quantity estimate of VP1/VP3 25 kDa band = 0.63 µg 
0.63 µg × (1mL /0.03mL)  
= 2.1 µg of desired FMDV VP1/VP3 capsid protein in total 1 mL fraction 25 
 
Total yield ≈ ∑ fractions 24, 25 
7.6 µg + 2.1 µg 
= 9.7 µg yield from 60 g fresh leaf mass 
= 1.616 × 10-7 or 0.00001616 % 






























Figure C. Coomassie stain of gel comparing P12A3C expressed in N. benthamiana, via pTRAc,, pEAQ and pRIC; lanes 6 – 9 respectively, 
purified with a 5% - 20% sucrose gradient. Agains Bovine Albumin Standard dilution series. Lane 1 = BAS 12.5 µg; Lane 2 = 6.25 µg; 
lane 3 = 3.13 µg; lane 4 = 1.56 µg; lane 5 = 0.78µg; lane 6 = pTRAc-P12A3C Fraction 12; lane 7 = pEAQ-P12A3C Fraction 12; lane 8 = 
pRIC-P12A3C Fraction 12; lane 10 = pTRAc-empty crude extract. Ladder used = NEB # P7712S boad range protein marker. 
